

# **National Program of Cancer Registries Cancer Surveillance System (NPCR-CSS)**

## **2021 Data Release Policy Diagnosis Years 1995–2020**

---

Policy Revised August 2021

Cancer Surveillance Branch  
Division of Cancer Prevention and Control  
NCCDPHP, CDC  
4770 Buford Hwy, N.E., Mailstop S107-4  
Atlanta, GA 30341-3717  
E-mail: [uscsdata@cdc.gov](mailto:uscsdata@cdc.gov) (specify “NPCR-CSS” in subject line)

## TABLE OF CONTENTS

I.	INTRODUCTION .....	1
A.	Summary of Changes .....	1
II.	OVERVIEW OF DATA .....	2
III.	DATA RELEASE ACTIVITIES .....	3
A.	Public Web-based Query Systems .....	3
1.	U. S. Cancer Statistics Data Visualizations Tool .....	4
2.	CDC WONDER .....	5
3.	Federal Partners Web-Based Systems .....	5
a)	Age-adjusted rates only .....	5
b)	Age-adjusted and crude rates .....	5
4.	Environmental Public Health Tracking Network Program .....	5
a)	Tracking Program Unsmoothed Rates .....	6
b)	Tracking Program Smoothed Rates .....	6
c)	Tracking Program National Portal to State Portal .....	6
5.	Indian Health Services .....	6
B.	Data Release to Federal and Trusted Partners .....	7
1.	American Cancer Society .....	7
2.	Central Brain Tumor Registry of the United States (CBTRUS) .....	7
3.	International Association of Cancer Registries (IACR) .....	8
a)	CI5 .....	8
b)	CI5plus .....	8
c)	IICC .....	8
4.	CONCORD .....	8
5.	Agency for Healthcare Research and Quality (AHRQ) .....	9
C.	Analytic datasets .....	9
1.	NPCR/SEER USCS Incidence Analytic Data .....	10
a)	NPCR Internal Survival Dataset .....	10
b)	NPCR/SEER Survival Dataset .....	10
c)	NPCR Internal Prevalence Dataset .....	10
d)	NPCR/SEER USCS Delay Adjusted Dataset .....	10
2.	NPCR/SEER USCS Incidence and Survival Public-Use Research Dataset .....	11
3.	Restricted-Access Research Dataset (RDC) .....	11
D.	Data Release Under Controlled Conditions .....	12
E.	Emergency and Provisional Data Releases .....	13
IV.	PROTECTION OF DATA .....	13
A.	Assurance of Confidentiality .....	13
B.	Suppression of Rates and Counts .....	13
C.	Public Release Disclosure Statement .....	14
D.	Freedom of Information Act (FOIA) Data Requests .....	14
E.	CDC External Data Requests .....	15
V.	REFERENCES .....	17

<b>TABLE 1</b>	Comparison of NPCR-CSS Data.....	19
<b>APPENDIX A</b>	State and Metro Area Cancer Registries.....	23
<b>APPENDIX B</b>	NPCR-CSS Overview of Data Security.....	25
<b>APPENDIX C</b>	Data Items for CBTRUS Dataset.....	25
<b>APPENDIX D</b>	NPCR/SEER USCS Analytic Data Use Agreement.....	29
<b>APPENDIX E</b>	CDC Nondisclosure Agreement.....	32
<b>APPENDIX F</b>	Data Items for NPCR/SEER USCS Internal Analytic Dataset.....	44
<b>APPENDIX G</b>	Data Items for NPCR Internal Survival Dataset.....	46
<b>APPENDIX H</b>	NPCR-CSS 308(d) Assurance of Confidentiality.....	48
<b>APPENDIX I</b>	NPCR-CSS 308(d) Assurance of Confidentiality FAQ.....	50
<b>APPENDIX J</b>	Data Items for NPCR/SEER USCS Incidence Public Use Dataset.....	53
<b>APPENDIX K</b>	NPCR Research Data Use Agreement.....	55
<b>APPENDIX L</b>	NPCR Data at the NCHS RDC Q&A.....	58
<b>APPENDIX M</b>	Data items for Restricted Access Research Dataset.....	63
<b>APPENDIX N</b>	NPCR-CSS Levels of Data Access.....	65
<b>APPENDIX O</b>	Data items for NPCR/SEER USCS Delay-Adjusted Database.....	67
<b>APPENDIX P</b>	Data items for NPCR Prevalence Database.....	68

**National Program of Cancer Registries  
Cancer Surveillance System  
2021 Data Release Policy  
August 2021**

**I. INTRODUCTION**

This document describes the format and content of data that the Centers for Disease Control and Prevention's National Program of Cancer Registries (NPCR) Cancer Surveillance System (CSS) releases or shares. This multi-year policy updates the July 2020 NPCR-CSS Data Release Policy. This policy applies to data submitted to the Centers for Disease Control and Prevention (CDC) for the 2021 NPCR-CSS data submission and for all future data submissions until a new policy is provided.

The NPCR-CSS Privacy Steward, as authorized by the Chief of the Cancer Surveillance Branch, clears all releases of state data, ensuring that the data are released according to the terms of the NPCR-CSS Data Release Policy.

It is possible that, in future years, data release practices or the content and format of released data may vary from those described in these guidelines. Such changes may occur as a result of improvements in the quality of the data, changes in information technology, and evolving data needs. However, if such variations occur, the data release practices will provide comparable protection (or more protection) for patient confidentiality to what is described in this policy. If it is anticipated that any data will be released with less protection (as determined by the NPCR-CSS Privacy Steward) for patient confidentiality than is described in this policy, NPCR central cancer registries will be notified and have ample time to respond before the data are released. This policy is reviewed annually by the NPCR-CSS Privacy Steward and other appropriate CDC staff members to determine whether revisions are needed.

**Summary of Changes**

- Updated description of NPCR-CSS IRB designation. Under the Common Rule the project is deemed to be a non-research public health surveillance project and annual IRB review is no longer necessary, page 3
- Updated description of the USCS Data Visualizations tool with software used to build the tool and new data to be displayed: Stage at Diagnosis and Survival by Stage, page 1
- Survival data is no longer published in the CDC WONDER tool. WONDER descriptions were updated on page 5.
- Added a description of the new NPCR/SEER Survival Dataset, page 10.
- Added new step of obtaining SEER Research Plus access before accessing USCS databases on pages 11 and 13.
- Clarified the reviewer process for the Restricted-Access Research Dataset, page 13.
- Aligned wording in the Suppression of Rates and Counts section to Table 1, to indicate that the suppression rule of fewer than 6 applies to restricted access data, page 16
- Updated diagnosis years available in Table 1.

- Updated data item lists for NPCR/SEER USCS Incidence Analytic Dataset (Appendix F), NPCR Internal Survival Dataset (Appendix G), NPCR/SEER USCS Incidence Public-Use Research Dataset (Appendix J)
- Updated text in Appendix H – NPCR-CSS 308(d) Assurance of Confidentiality Statement to match the currently approved Assurance of Confidentiality project description.

## II. OVERVIEW OF DATA

In 1992 Congress established NPCR by enacting the Cancer Registries Amendment Act, Public Law 102-515.<sup>4</sup> The law authorized CDC to provide funds and technical assistance to states and territories to improve or enhance existing cancer registries and to plan for and implement population-based central cancer registries where they did not exist. NPCR’s purpose is to assure the availability of more complete local, state, regional, and national cancer incidence data for the planning and evaluation of cancer control interventions and for research. NPCR adopted reporting requirements and definitions consistent with the National Cancer Institute’s (NCI) Surveillance, Epidemiology, and End Results Program (SEER);<sup>11,12</sup> required the use of uniform data items, codes, and record layouts as defined by the consensus of members of the North American Association of Central Cancer Registries (NAACCR);<sup>13</sup> and established standards for data management and data completeness, timeliness, and quality similar to those recommended by NAACCR.<sup>13,14</sup> In 1994, the first 37 States received funding from CDC.<sup>15</sup> Currently, 46 States, the District of Columbia, Puerto Rico, the U.S. Virgin Islands, and the U.S. Pacific Island Jurisdictions are funded by NPCR (appendix A).<sup>16</sup> NPCR-funded central cancer registries collect data on patient demographics, primary tumor site, morphology, stage of disease at diagnosis, and first course of treatment. In addition, NPCR central cancer registries conduct follow-up for vital status by linking with state and national death files or active case follow-up.

Invasive and *in situ* cancer case reports are submitted to CDC by population-based statewide central cancer registries in all 46 participating states, the District of Columbia, Puerto Rico, Virgin Islands, and the U.S. Pacific Island Jurisdictions. In each state or territory, state laws and regulations mandate the reporting of cancer cases by facilities and practitioners who diagnose or treat cancer to the state health department or its designee.<sup>4</sup> The central cancer registry receives case reports from facilities and practitioners throughout the state and processes them according to standard data management procedures.<sup>14</sup> Personal identifiers including the patient’s name, Social Security number, and street address are removed from the NPCR-CSS submission prior to the encryption and electronic transmission of these case reports to a contractor acting on behalf of CDC. CDC and the contractor adhere to strict data security procedures when receiving, processing, and managing the data (appendix B). CDC has an Office for Human Research Protections (OHRP)-approved, federal-wide assurance of compliance with rules for the protection of human subjects in research ([45 Code of Federal Regulations 46](#)). NPCR-CSS received formal approval (protocol #2594) from CDC’s Institutional Review Board (IRB) in October 1999 and annual approval was sought and approved through 2020. In 2021, under the Common Rule ([45 Code of Federal Regulations Part 46, Common Rule 2018](#)), NPCR-CSS was deemed to be a non-research public health surveillance project and annual IRB review is no longer necessary.

Central cancer registries and federal agencies routinely publish cancer incidence data 23 months after the close of each diagnosis year based on data that meet data quality standards.<sup>16,17</sup> However, other versions of the same data, based on the data file as it exists at different time periods, are usually available. For example, some central cancer registries have preliminary data available as soon as 12 months after the close of each diagnosis year. After the publication of official statistics, central cancer registries (as well as CDC and NCI) continue to update and republish data with new information incorporated. When cancer incidence data are published, it is common practice to document either the data submission date (i.e., when the data were submitted to CDC or NCI) or the date that the file was prepared. Changes in central cancer registry incidence data that occur more than 22 months after the close of a diagnosis year are likely to be small; however, delays in reporting are more likely to impact certain cancer sites and may be important for some research studies.<sup>18</sup>

CDC generates multiple data products using NPCR-only data and combined NPCR and SEER data. The combined NPCR and SEER data are referred to as U.S. Cancer Statistics (USCS). USCS is the official federal cancer statistics, providing the most up-to-date information on the *entire* U.S. population.

### **III. DATA RELEASE ACTIVITIES**

Starting with DP17-1701, participation in all CDC-created and hosted analytic datasets and web-based data query systems, as outlined in this policy, is a required strategy.<sup>1</sup> Therefore, the NPCR-CSS Dataset Participation Agreement is no longer provided.

#### **A. Public Web-based Query Systems**

For purposes of this policy, public web-based query systems are defined as datasets that are comprised of aggregated data (i.e., not individual case-specific data or microdata) that have been modified according to accepted procedures to block breaches of confidentiality and prevent disclosure of the patient's identity or confidential information and have a database behind a CDC firewall that is either case-specific microdata or pre-analyzed data tables.<sup>2, 5-10</sup> Users are able to access only aggregate counts and rates with all confidentiality protections built in. A combination of confidentiality protection measures is employed for each public web-based query system (see [Table 1](#)). These systems do not contain information that is identifiable or potentially identifiable according to currently accepted procedures for reducing disclosure risk.<sup>2, 5-10</sup> Before each system is finalized, the aggregate values are analyzed to determine whether there is a need for complementary cell suppression.<sup>2, 5-10</sup> If appropriate, the analysis includes consultation with a statistician with specific expertise in statistical disclosure limitation techniques. Following the analysis, complementary cell suppression is applied as needed.

There are no restrictions on access to public web-based query systems. A public release disclosure statement (see IV.C. Public Release Disclosure Statement) cautions users against

---

<sup>1</sup> DP17-1701, 2. CDC Project Description, a. Approach, iii. Strategies and Activities, Program 3: National Program of Cancer Registries (NPCR) – Component 1, Strategy 3 Cancer Data and Surveillance (Domain 1), Data Submission (page 19)

inappropriate use of the data or inappropriate disclosure of information. Data are released as delimited ASCII files, a web-based query system, or possibly through other data products (see [Table 1](#)). As a convenience to NPCR central cancer registries, states may request from CDC a copy of their complete state-specific analytic database that is used to populate each public web-based query system. The following public web-based query systems are currently being released:

- USCS Data Visualizations tool
- CDC WONDER – USCS incidence and incidence/mortality rate ratios
- Federal partner’s web-based query systems
  - NCI’s State Cancer Profiles
  - CDC’s Environmental Public Health Program’s Tracking Network
  - Chronic Disease Indicators (CDI) website and data portal
  - Office on Women’s Health’s Health Information Gateway

All NPCR-CSS public web-based query systems consist of cancer incidence data selected from the NPCR/SEER analytic database. This is the same database that provides cancer incidence data for the annual release of USCS data products, including the Data Visualizations tool, public use database and State Cancer Profiles. Data sources, case definitions, basic registry eligibility criteria in terms of required data quality, population denominator sources, methods for calculating incidence rates, and the rationale for specific cell suppression thresholds are as described in the USCS [Data Visualizations Tool Technical Notes](#), unless noted in separate documentation that accompanies the data.

Separate documentation may accompany each data product that describes its unique features (e.g., the data submission date, percentage of the U.S. population covered, diagnosis years and cancer sites included, variables included, data suppression rules, any special data quality criteria required for inclusion, and any unique statistical methods employed).

## **USCS Data Visualizations Tool**

The USCS Data Visualizations tool is a web-based application built with D3 Java Script libraries, React framework, and web APIs, that outputs data in hypertext markup language (HTML) file containing the aggregate counts and rates for incidence, mortality, prevalence and survival estimates published annually, along with text documentation and data visualizations. The tool is available at [www.cdc.gov/cancer/dataviz](http://www.cdc.gov/cancer/dataviz). It currently displays single year and 5-year aggregate counts, crude rates, age-adjusted rates, and 95-percent confidence intervals by primary site, sex, race, and ethnicity at the county (5-year aggregate), Congressional districts (5-year aggregate), state, and national levels. Congressional district estimates (estimated 5-year aggregate counts, age-adjusted rates) are presented by sex, race, and ethnicity (all races/ethnicities, non-Hispanic White, Black, and Hispanic). In addition, cancers grouped by associated risk factors are presented by state, sex, race, and age-group (single year and 5-year aggregate) are presented in Data Visualizations tool. Data by stage at diagnosis and survival by stage for select sites are presented by sex, race/ethnicity, and age at the national level. Stage at diagnosis is categorized as localized, regional, distant, and unknown/unstaged. Preliminary and delay-adjusted incidence rates and counts, as well as other newly identified indicators, may be published in the tool. The Data Visualizations tool’s database is behind a CDC firewall with pre-tabulated data created using SEER\*Stat queries, which allows for the display of counts and rates

that meet suppression and confidentiality protections. Users can access only aggregate counts and rates with all confidentiality protections built in. Downloadable ASCII files with the pre-tabulated data are available from CDC's website. States may request a state-specific web API.

### **CDC WONDER – USCS Incidence, Mortality, and Incidence/Mortality Ratios**

The USCS dataset available on [CDC WONDER](#) displays the aggregate incidence and mortality counts, rates, and 95-percent confidence intervals, by primary site, sex, race, and ethnicity at the state, county, regional, Metropolitan Service Areas (MSA), and national levels. Cancer incidence/mortality rate ratios (by year, state, MSA, race, ethnicity, sex, and cancer site) are also available. The WONDER database is stored behind a CDC firewall with case-specific microdata. Users are only able to access only aggregate counts and rates with all confidentiality protections built in.

The WONDER tool allows users more flexibility in creating cross-tabulations than the Data Visualizations tool. While the same underlying USCS data are available in the two tools, more detailed breakdowns of counts and rates are available through WONDER. The additional values result from variable selections that are not currently available in the Data Visualizations tool (see [Table 1](#)) and include results for Metropolitan Service Areas that have met the population threshold of 50,000 or more and standard 5-year age groups that can be combined by the user.

### **Federal Partners' Web-based Systems**

CDC shares aggregated data with federal partners for display in their web-based query systems. The data are generated specifically for the partners' needs and are shared via ASCII files. Unless otherwise noted below, the data generally consists of aggregate cancer incidence counts, crude rates, and age-adjusted rates for selected primary sites, age groups, and counties in the United States (see [Table 1](#) for more details).

Future versions may contain more detail about cancer at the county level. Beginning in 2008, CDC began routinely publishing county data averaged over 5 years.

#### ***Age-adjusted rates only***

[State Cancer Profiles](#) is a web-based query tool that public health professional can use to prioritize cancer control efforts at the county-, state-, and national-level. Data are released to NCI SEER for the development of the State Cancer Profiles data product, which presents average annual counts and age-adjusted incidence and mortality rates only.

#### ***Age-adjusted and crude rates***

Data released to the U.S. Department of Health and Human Services, Office of Women's Health (OWH) includes crude and age-adjusted rates. The data are available through their online tool, [Health Information Gateway](#).

#### ***Environmental Public Health Tracking Program***

USCS data are provided to the CDC's National Center for Environmental Health's [Environmental Public Health Tracking Program](#) (Tracking Program) for display on the Tracking Network and through dashboards on CDC's Division of Cancer Prevention and Control's (DCPC) website. The Tracking Network displays single-year and 5-year aggregate incidence



counts, age-adjusted rates, and 95-percent confidence intervals for selected primary sites and age groups for selected geographic areas (see [Table 1](#)). Single-year can be viewed at the state-level; data by 5-year average and 5-year summed are available at the county-level; data by 3-, 5-, 7-, and 10-year aggregate are available at the subcounty level.

Maps of incidence counts and incidence rates for select cancers will be displayed for various sub-county geographies. Incidence rates are based on incidence counts stratified by census tract, year of diagnosis, age group (standard 19 groups), sex and Census-based population estimates. These incidence counts and age-adjusted rates are displayed using spatial aggregation (census tract, geographies with a minimum of 5,000 persons, or geographies with a minimum of 20,000 persons) and temporal aggregation (3-, 5-, 7-, or 10-year periods) schemas recommended by a subcounty cancer data workgroup. Rates are age-adjusted to the 2000 US standard population. Counts and rates are suppressed when there are <16 cases or <100 persons in the geographic area. Specific to this project, an additional suppression is applied when the relative standard error of the rate is >30%.

The Tracking Program's [web-based query system](#) runs using a database behind a CDC firewall with case-specific microdata, which allows for the calculation of locally-weighted smoothed rates or unsmoothed rates, or both:

- **Tracking Program Unsmoothed Rates**  
Data published are like those on State Cancer Profiles. It includes cancer data from all 50 states.
- **Tracking Program Smoothed Rates**  
Smoothing is the process of averaging a measure for an area based on information about that area and areas around it. Please note that the main purpose of smoothing is to clarify spatial patterns and to improve the stability of rates, not to prevent disclosure of private information. Back-calculation of case counts from smoothed rates is sometimes possible when the method of smoothing is made known and (non-sensitive) denominator data are available from other sources.

Through the Tracking Program, users can access only aggregate counts and rates with all confidentiality protections built in.

- **Tracking Program National Portal to State Portal**  
CDC's Tracking Program has grantees in several NPCR-funded states that are responsible for the state-level public portals. In collaboration with the Tracking Program, upon request, CDC-NPCR provides the state-level Tracking Network dataset to the Tracking Program state counterpart.

## **Indian Health Services (IHS)**

CDC continues to use the IHS linkage results for analyses of cancer incidence among American Indian and Alaska Native populations. In addition to improving cancer incidence rates presented in USCS Data Visualization tool, an analytic database is maintained by a CDC Division of Cancer Prevention and Control employee assigned to IHS. Access to this database is limited to approved CDC staff. The data are used to respond to data requests for American Indian and Alaska Native populations cancer incidence rates from tribal epidemiology centers and tribal

organizations. Five-year aggregate incidence counts, age-adjusted rates, and 95-percent confidence intervals for selected primary sites are displayed in the USCS Data Visualizations tool (see [Table 1](#)). These data are limited to non-Hispanic American Indian and Alaska Native people living in IHS Purchased/Referred Care Delivery Areas (PRCDA) counties. Inclusion in this dataset also allows IHS to *provide the state with the date of death obtained through NDI-IHS linkage and/or the date the linkage occurred by diagnosis year, for registries that complete an NDI supplemental confidentiality agreement for application Y9-0033.*

## **B. Data Release to Federal and Trusted Partners**

### **American Cancer Society (ACS)**

CDC shares NPCR and USCS data with ACS to promote collaborations on cancer surveillance and epidemiological research efforts. ACS's Surveillance and Health Services Research (SHSR) Program analyzes and disseminates cancer statistics and identifies gaps and opportunities for cancer prevention, early detection and treatment. The SHSR annually publishes the statistical report, *Facts and Figures*, and peer-reviewed journal articles that are used by public health experts, clinicians, and scientists.

In 2018, a Memorandum of Understanding was implemented with the American Cancer Society, and ACS staff members must sign a Data Use Agreement form and complete annual Assurance of Confidentiality training before s/he is given access to the data. Beginning in 2020, due to changes in SEER's data release policy, CDC also obtains approval from SEER before releasing USCS data. CDC provides ACS staff access to the following databases with record level data through SEER\*Stat software: USCS delay-adjusted database, NPCR survival database, NPCR prevalence database, and selected variables from the NPCR and SEER Quality Control database. The Quality Control database shared with ACS is restricted to 24-month data, excludes postal code and census tract variables, and excludes "day" fields for date of birth and date of death.

### **Central Brain Tumor Registry of the United States (CBTRUS)**

CBTRUS annually publishes the print and Web versions of the statistical report, *Primary Brain Tumors in the United States Statistical Report Supplement*; a previous version of the report is available at: <https://www.cbtrus.org/reports>. The report includes age-adjusted rates and corresponding 95-percent confidence intervals on brain and other central nervous system tumors and is presented by state, histology, major histology grouping, primary site, behavior, gender, race, ethnicity, and age at diagnosis. As a trusted partner, CBTRUS is provided access to the NPCR Survival Dataset to include survival estimates in the annual report, conduct in-depth analyses, and respond to queries. CDC provides individual, record-level data to CBTRUS for the publication of this report; Appendix C lists the variables included in this dataset. Only states meeting the USCS publication criteria are included in the dataset.

In addition, CBTRUS uses these data to respond to inquiries that are more specific than those that are provided by the report. For these inquiries, no individual record level data are released; only aggregated data with the corresponding confidence intervals (if applicable) and appropriate suppression criteria are provided to data inquirers. Attribution to NPCR is provided. CBTRUS

signs data use agreements before data are released for their report and future inquiries. For questions, contact CBTRUS staff at [cbtrus@aol.com](mailto:cbtrus@aol.com).

## **International Association of Cancer Registries (IACR)**

The [International Association of Cancer Registries](#) (IACR) produce the *Cancer Incidence in Five Continents* (CI5) and the *International Incidence of Childhood Cancer* (IICC). The [CI5 series](#) of monographs, published every five years, has become the reference source of data on the international incidence of cancer. The most recent version was published in 2017. The CI5 databases provide access to detailed information on the incidence of cancer recorded by cancer registries (regional or national) worldwide in two formats (CI5 and CI5plus) and the IICC provides access to detailed information on the incidence of pediatric cancers:

- **CI5**  
Presents the basic data published in the CI5 volumes.
- **CI5plus**  
Contains annual incidence for selected cancer registries published in CI5 for the longest possible period.
- **IICC**  
Presents basic pediatric data.

When IACR requests data, the formal Call for Data Submission giving information on the evaluation procedure, likely layout of how data will be presented, and questionnaire on registry operations will be available from the IACR website. CDC-NPCR may facilitate the call for data on behalf of awardees. CDC-NPCR will provide additional information regarding the CI5 Call for Data as it becomes available. There are two components of the CI5 Call for Data: 1) the questionnaire and introductory text and 2) data submission.

Data submitted for CI5 may also be used for the IICC publication making a separate data submission unnecessary. This IACR product does require a separate questionnaire and introductory text to be completed by the states.

States are responsible for completing the on-line questionnaires and providing an introductory text, indicating if the CI5 data and introductory text are also used for the IICC product. CDC-NPCR will submit aggregated NPCR data for central cancer registries meeting USCS publication criteria.

## **CONCORD**

[CONCORD](#) is the global program for world-wide surveillance of cancer survival and is led by the London School of Hygiene & Tropical Medicine and supported by the Union for International Cancer Control (UICC). CONCORD monitors progress towards the overarching goal of the UICC World Cancer Declaration made in 2013: “major reductions in premature deaths from cancer, and improvements in quality of life and cancer survival”.

A call for participation in the CONCORD studies is periodically issued and extends examination of world-wide cancer survival trends for certain cancer sites: i.e., stomach, colon, rectum, liver,

lung, breast, cervix, ovary, prostate, esophagus, pancreas, and melanoma of skin in adults, as well as leukemias, lymphomas, and brain tumors in adults and children (0-14 years). The protocol and dataset specifications are posted to NPCR-CSS Document Server, CONCORD tab as they become available.

CDC-NPCR may facilitate the call for data on behalf of awardees by submitting NPCR data for central cancer registries meeting USCS publication criteria for survival analyses (meet USCS data quality criteria and have conducted active patient follow-up or linked records with the National Death Index).

## **Agency for Healthcare Research and Quality (AHRQ)**

Health and Human Service's Agency for Healthcare Research and Quality (AHRQ) is the lead federal agency charged with improving the safety and quality of America's health care system. It develops and disseminates knowledge, tools, and data to improve health care systems and help Americans, health care professionals, and policy makers make informed health decisions. NPCR-CSS data are shared with AHRQ for reports on [national healthcare quality and disparities](#).

### **C. Analytic datasets**

#### **USCS Analytic Data**

Combined NPCR and SEER incidence data are referred to as U.S. Cancer Statistics (USCS). CDC creates USCS Analytic Datasets each year that include data from central cancer registries meeting USCS publication criteria and diagnosis year coverage. CDC, NCI staff members, and contractors perform analyses of USCS data as needed using these internal analytic databases.

The datasets are made available via SEER\*Stat software to federal employees, fellows, and contractors in the CDC's Division of Cancer Prevention and Control and NCI's SEER Program after obtaining SEER Registry Plus access, signing a *NPCR Analytic Data Use Agreement* (Appendix D) and *CDC Nondisclosure Agreement* (Appendix E) and completing annual Assurances of Confidentiality training. The dataset is also available to approved partnering organizations and state central cancer registries after a Memorandum of Understanding and Data Use Agreements are signed (see [Appendix H](#) and [Appendix I](#)).

In specially established collaborative relationships, researchers external to CDC, NCI, and ACS may be provided access to the USCS analytic datasets. In these relationships, CDC staff must be included in the analytic project as a co-author, Data Use Agreements must be signed, and Assurance of Confidentiality training must be completed before access will be provided. Additionally, access will only be allowed on-site at CDC's Cancer Surveillance Branch offices. See the section "External Data Requests".

Cancer surveillance and epidemiological analyses include assessment of the completeness, timeliness, and quality of cancer incidence data and analyses of the cancer burden and survival as needed for meeting national cancer control objectives. Such analyses of state and national data are conducted routinely by federal agencies, including CDC and NCI, for programmatic or statistical purposes, as needed, to achieve the agencies' mandates.

There are five internal analytic datasets routinely analyzed by CDC and NCI staff members:

***NPCR/SEER USCS Incidence Analytic Dataset***

CDC and NCI staff members and contractors conduct cancer surveillance and epidemiological research that result in publications, data briefs, and presentations. Examples of research include descriptive analyses by racial and ethnic populations for specific cancers, descriptions of cancer incidence trends, and descriptive analyses of the quality of the data. Appendix F lists the variables available in this dataset.

***NPCR Internal Survival Dataset***

Cancer survival data are critical for evaluating the progress and impact of early detection/screening programs and/or comprehensive cancer control plans as well as interventions from other sources. CDC's NPCR-CSS calculates and publishes survival estimates on this population at the national, state, and regional levels. Focusing on the entire NPCR-CSS dataset supports analyses of survival estimates for rare cancers that cannot be addressed otherwise and provides data for publication on the USCS Data Visualizations tool. Appendix G lists the variables available in this dataset.

***NPCR/SEER Survival Dataset***

This database contains data from NPCR- and SEER-funded registries that have completed National Death Index linkages or active patient follow-up for all years included in the database and meet 95% completeness estimates. This dataset will be used to assess Healthy People 2030 cancer objective C-11: Increase the proportion of cancer survivors who are living 5 years or longer after diagnosis. The list of variables included in the dataset are the same as the NPCR Internal Survival Data, which are listed in Appendix G.

***NPCR Internal Prevalence Dataset***

This database provides limited duration prevalence estimates for NPCR registries who meet USCS publication criteria for all years included in the database and that have completed National Death Index linkages or active patient follow-up for all years included in the database. Statistics generated from this dataset are published on the USCS Data Visualizations tool. The list of variables available in this dataset are in Appendix O.

***NPCR/SEER USCS Delay-Adjusted Dataset***

Case-reporting delay may result in an underestimate of true incidence. Researchers can adjust for this delay using composite delay factors, thus producing more precise cancer incidence trends. The [composite delay factors](#) used in this database were developed by SEER and are used by NPCR, SEER, and NAACCR. The delay-adjustment factors account for cancer site, registry, age, race, ethnicity, and diagnosis year, and are used to estimate delay-adjusted counts and rates. The list of variables available in this dataset are in Appendix P.

In compliance with the 308(d) Assurance of Confidentiality, CDC and NCI employees and contractors and partner organizations conducting these analyses are required to handle the information in accordance with principles outlined in the CDC Staff Manual on Confidentiality and to follow the specific procedures documented in the NPCR-CSS Confidentiality/Security Statement (appendices B, H, and I).

In addition, CDC, SEER, and partner organization staff members are required to acknowledge state cancer registries whenever NPCR-CSS data are presented, released, or published by CDC by making available the following (or similar) statement:

*These data were provided by central cancer registries participating in the National Program of Cancer Registries (NPCR) and submitted to CDC in [Month, Year], and/or the Surveillance, Epidemiology and End Results (SEER) program and submitted to NCI in [Month, Year]. The dataset includes data for diagnosis years 1998-xxxx (excluding SEER-Metro Registry data).*

### **NPCR/SEER USCS Incidence and Survival Public-Use Research Dataset**

For purposes of this policy, the NPCR/SEER USCS Incidence Public-Use Research Dataset (Incidence PUD) and the NPCR Survival Public-Use Research Dataset (Survival PUD) are defined as the version of the full NPCR/SEER USCS microdata (i.e., individual case-specific data) that have been modified as needed to minimize the potential for disclosure of confidential information. These datasets contain a subset of data items published in the NPCR/SEER USCS Incidence Analytic dataset. Personal identifiers, such as a patient's name, street address, or Social Security number, are not included in these datasets as this information is not transmitted by central cancer registries to CDC as part of their annual data submission. Certain data items, such as date of birth and reporting-source (death certificate only and autopsy only) cases, may be removed from these research datasets to minimize the potential identification of individuals with the occurrence of rare cancer in a person of certain age or racial or ethnic group or living in a specific county. The list of the variables included in the NPCR/SEER USCS Incidence Public-Use Dataset is in Appendix J. The NPCR Survival Public-Use Research Dataset is under development. Before releasing the Survival PUD, the NPCR CSS Data Release Policy will be updated.

The Incidence PUD dataset, previously only available to NPCR Registry Staff, is now available publicly through SEER\*Stat software. Upon completion, the Survival PUD will be made available through the same mechanism. Researchers are given access to the data after obtaining SEER Registry Plus access and signing an *NPCR and SEER – U.S. Cancer Statistics Research Data Use Agreement* (Appendix K). A Public Release Disclosure Statement cautions users against inappropriate use of the data or inappropriate disclosure of information. Cell suppression of <16 cases is automatic and the SEER\*Stat case listing function is disabled as additional data protection measures. This dataset allows the authorized counts, crude rates, age-adjusted incidence rates, and 95-percent confidence intervals to be generated by the authorized user to meet their specific needs.

### **Restricted-Access Research Dataset (RDC)**

For purposes of this policy, the restricted-access dataset is defined as the version of the full NPCR/SEER USCS analytic dataset, either aggregated data or microdata (i.e., individual case-specific data) that has been modified as needed to minimize (but may not remove entirely) the potential for disclosure of confidential information.

CDC uses the National Center for Health Statistics Research Data Center (NCHS RDC) as a mechanism for researchers outside of the Division of Cancer Prevention and Control (DCPC) to request and gain access to NPCR data for research purposes. The data are available through the NCHS RDC only after the standard data quality reviews that occur as part of the preparation for USCS. The restricted-access dataset is released to researchers through the NCHS RDC after CDC authenticates the requestor's identity and research intent through an extensive proposal review process and after the researcher completes the NCHS RDC confidentiality and security requirements. The requestor must also comply with the confidentiality procedures at and data sharing agreements with the NCHS RDC.

The NCHS RDC has developed and maintains detailed data sharing agreements and procedures for user authentication and for logging and monitoring of data releases. Proposed project proposals are reviewed by CDC, which includes NPCR and NCHS RDC staff. Proposals may also be shared for review with central cancer registry staff whose data are included in the proposed project. User documentation includes a data dictionary for every diagnosis year available at the NCHS RDC.

The use of the NCHS RDC to manage data access provides the highest level of data security and protection of confidentiality that is available for data analysis. Using the NCHS RDC allows CDC to comply with the Assurance of Confidentiality [308(d)] that was obtained for the NPCR-CSS data. The NCHS RDC is also covered by a separate Assurance of Confidentiality [308(d)].

For further information regarding the NCHS RDC, refer to Appendix L of this policy.

The restricted-access dataset does not contain personal identifiers such as a patient's name, street address, or Social Security number as this information is not transmitted by central cancer registries to CDC as part of their annual data submission. However, the dataset may contain information that is potentially identifiable especially when linked with other datasets, such as the occurrence of a rare cancer in a person of a certain age or racial or ethnic group or living in a specific county. The data are made available to researchers through a SAS dataset. The RDC staff creates a SAS dataset specific to each project. Researchers must include a data dictionary in their proposal and only the requested variables are included in the SAS file.

#### **D. Data Release Under Controlled Conditions**

CDC-wide policy stipulates that a CDC program may consider release of data that cannot be released as either a public web-based system, a research dataset, or restricted-access dataset under certain controlled conditions.<sup>1</sup> These controlled conditions may include a CDC-controlled data center such as the data center established at [National Center for Health Statistics \(NCHS\)](#), on-site at CDC's Cancer Surveillance Branch offices, or through special licensing. Except as described above, NPCR-CSS data will not otherwise be released under these controlled conditions while the current policy is in place. Release of data under controlled conditions will be considered as part of discussions with partners, and a determination will be made as to whether such releases of data will be considered for NPCR-CSS data.

## **E. Emergency and Provisional Data Releases**

It is not anticipated that CDC will need to release NPCR-CSS data before the files have been modified as needed to protect confidentiality as described in this policy. This is prohibited by the 308(d) Assurance of Confidentiality (appendices B, H, and I).

Provisional data and draft data tables may be shared with CDC employees and contractors, NPCR central cancer registries, and other partners in order to facilitate quality reviews of the data. When appropriate, individuals who participate in such reviews sign a *NPCR Analytic Data Use Agreement* and a *CDC Nondisclosure Agreement* (when applicable) before accessing the data or tables.

## **IV. PROTECTION OF DATA**

### **A. Assurance of Confidentiality**

All data collected and maintained by NPCR-CSS must be managed, presented, published, and released with strict attention to confidentiality and security, consistent with the general principles and guidelines established by CDC for confidential case data<sup>1-3</sup> and specific restrictions imposed on NPCR-CSS data (appendices B, H, and I).<sup>4</sup> Special care must be given to cancer incidence data that are not directly identifiable because geographic and small cell data may be indirectly identifying when combined with detailed information in case reports, laboratory reports, medical records, or linkage with other data files.<sup>5-10</sup>

NPCR-CSS has approval for protection under section 308(d) of the Public Health Services (PHS) Act (42 U.S.C. 242m(d)) (appendices B, H, and I). The 308(d) confidentiality assurance protects identifiable and potentially identifiable information from being used for any purpose other than the purpose for which it was collected (unless the person or establishment from which it was obtained has consented to such use). This assurance protects against disclosures under a court order and provides protections that the Privacy Act of 1974 (5 U.S.C. 552a) does not. For example, the Privacy Act of 1974 protects individual participants, but the 308(d) confidentiality assurance also protects institutions. Confidentiality protection granted by CDC promises participants and institutions that their data will be shared only with those individuals and institutions listed in the project's consent form or in its specified policies.

### **B. Suppression of Rates and Counts**

When the numbers of cases or deaths used to compute rates are small, those rates tend to have poor reliability. Another important reason for using a threshold value for suppressing cells is to protect the confidentiality of patients whose data are included in a report by reducing or eliminating the risk of disclosing their identity.

Therefore, to discourage misinterpretation or misuse of rates or counts that are unstable because case or death counts are small, annual incidence and death rates and counts in publicly available datasets and web-based query systems are suppressed if the case or death counts are below 16. A count of fewer than about 16 results in a standard error of the rate that is approximately 25% or more as large as the rate itself. Similarly, a case count below 16 results in the width of the 95% confidence interval around the rate being at least as large as the rate itself. These relationships were derived under the assumption of a Poisson process and with the standard population age



distribution assumed to be similar to the observed population age distribution. For aggregated time periods, counts and rates are suppressed for less than 16 cases. However, average annual rates and counts may not be suppressed if the total case count for the time period exceeds 16.

The cell suppression threshold value of 16, which was selected to reduce misuse and misinterpretation of unstable rates and counts, is more than sufficient to protect patient confidentiality.

Per the Data Use Agreements, researchers using restricted access data files are required to suppress count and statistical results that are based on cells with fewer than 6 cases in publications and presentations. Researchers are advised to use caution when presenting or interpreting results based on less than 16 cases.

Complementary cell suppression and suppression of certain race and ethnicity combinations are required as additional measures to assure confidentiality and stability.

### **C. Public Release Disclosure Statement**

The following (or similar) public release disclosure statement is prominently displayed for users of all NPCR-CSS public web-based query systems, research datasets, and restricted-access datasets:

*Data Use Restrictions: Read Carefully Before Using*  
***By using these data, you signify your agreement to comply with the following statutorily based requirements.*** *The National Program of Cancer Registries (NPCR), Centers for Disease Control and Prevention (CDC), has obtained an assurance of confidentiality pursuant to Section 308(d) of the Public Health Service Act, 42 U.S.C. 242m(d). This assurance provides that identifiable or potentially identifiable data collected by the NPCR may be used only for the purpose for which they were obtained unless the person or establishment from which they were obtained has consented to such use. Any effort to determine the identity of any reported cases, or to use the information for any purpose other than statistical reporting and analysis, is a violation of the assurance. Therefore users will:*

- *Use the data for statistical reporting and analysis only.*
- *Make no attempt to learn the identity of any person or establishment included in these data.*
- *Make no disclosure or other use of the identity of any person or establishment discovered inadvertently, and advise the Associate Director for Science, Office of Science Policy and Technology Transfer, CDC, Mailstop D-50, 1600 Clifton Road, N.E., Atlanta, Georgia, 30333, Phone: 404-639-7240) (or NCI's SEER Program if SEER data) and the relevant state or metropolitan area cancer registry, of any such discovery.*

### **D. Freedom of Information Act (FOIA) Data Requests**

The Freedom of Information Act (FOIA) (<http://www.cdc.gov/od/foia/>) generally provides that, upon written request from any person, a federal agency (i.e., CDC) must release any agency

record unless that record falls (in whole or part) within one of nine exemptions. FOIA applies to federal agencies only and covers only records in the possession and control of those agencies at the time of the FOIA request (except in certain instances involving grantee-held data). Because state-based data become a federal record in CDC's possession, such records are subject to disclosure in response to a FOIA request. The FOIA exemptions that may be available to protect some aspects of state data from public disclosures in response to a FOIA request are:

- Exemption 3, which specifically exempts information from disclosure by statute (in this instance, pursuant to an Assurance of Confidentiality under Section 308(d) of the Public Health Service Act), and
- Exemption 6, which exempts from disclosure personnel and medical files and similar files, which would constitute an unwarranted invasion of personal privacy.

In general, non-FOIA requests to CDC from the public, media, and other government agencies for local cancer incidence data are referred to the state health department for a reply. There are three reasons for this: (1) the state health departments can release cancer incidence data in accordance with locally established policies and procedures and consistent with provisions of the Cancer Registries Amendment Act (Public Health Service Act, (42 USC 280e-280e-4), as amended);<sup>4</sup> (2) the relative infrequency of data submission to federal agencies assures that the state health department or its designated central cancer registry will have the most complete, accurate, and up-to-date information; and (3) the central registry may be able to provide more detailed data that can better meet the needs of the requestor. When the request is for data regarding cancer incidence involving more than one state, CDC will refer the requestor to published reports or to NPCR-CSS datasets that are released in accordance with practices described in this document, if relevant.

### **E. CDC External Data Requests**

Individuals, agencies, or organizations outside CDC may request data not available from a public web-based query system or research dataset. When the requests do not identify a state, CDC staff members or contractors tabulate the data for the inquirer. For requests that identify a state, CDC staff members may seek states' permission regarding use. See Appendix N for additional details.

Researchers may submit data query or study proposal requests for the NPCR/SEER USCS Incidence Analytic Dataset to CDC. These requests must include:

- Names of individuals who will need access to the data
- Purpose and public health significance of the investigation
- Research question(s)
- Variables required beyond those in the freely-available research data
- Subset of cases needed (specifically cancer type, data years, registries)
- Planned use of data (e.g., manuscript, poster, presentation)

After CDC authenticates the requestor's identity and research intent, and verifies that confidentiality is maintained, a CDC analyst will process the data query and provide results to the researcher. The requestor must comply with all confidentiality and data suppression procedures outlined in the NPCR-CSS Assurance of Confidentiality [308(d)].

In circumstances where the researcher requires access to the USCS Analytic Datasets:

- CDC staff must be included in the analytic project as a co-author
- Data Use Agreements must be signed
- Assurance of Confidentiality training must be completed
- Access is only allowed on-site at CDC's Cancer Surveillance Branch offices.

## V. REFERENCES

1. Centers for Disease Control and Prevention. *CDC/ATSDR Policy on Releasing and Sharing Data*. Atlanta: Centers for Disease Control and Prevention; 2003. Available at <http://www.cdc.gov/maso/Policy/ReleasingData.pdf>.
2. Centers for Disease Control and Prevention. *CDC/ATSDR/CSTE Data Release Guidelines for Re-Release of State Data*. Atlanta: Centers for Disease Control and Prevention; 2003 (available upon request).
3. Centers for Disease Control and Prevention. *CDC Staff Manual on Confidentiality*. Atlanta: Centers for Disease Control and Prevention; 1984 and National Center for Health Statistics. *NCHS Staff Manual on Confidentiality*. Hyattsville, MD: National Center for Health Statistics; 1999.
4. Cancer Registries Amendment Act, Public Law 102-515, Stat. 3312 (October 22, 1992). Available at <http://www.cdc.gov/cancer/npcr/npcrpdfs/publaw.pdf>.
5. American Statistical Association. *Data Access and Personal Privacy: Appropriate Methods of Disclosure Control*. Alexandria, VA: American Statistical Association; 2008. Available at <https://www.amstat.org/asa/files/pdfs/POL-DataAccess-PersonalPrivacy.pdf>.
6. Doyle P, Lane JI, Theeuwes JM, Zayatz LM (eds). *Confidentiality, Disclosure, and Data Access: Theory and Practical Application for Statistical Agencies*. Amsterdam: Elsevier Science BV; 2001.
7. Federal Committee on Statistical Methodology. *Checklist on Disclosure Potential of Proposed Data Releases*. Available at [https://nces.ed.gov/FCSM/doc/checklist\\_799.doc](https://nces.ed.gov/FCSM/doc/checklist_799.doc).
8. Federal Committee on Statistical Methodology. *Report on Statistical Disclosure Limitation Methodology. (Statistical Working Paper 22)*. Washington, DC: Office of Management and Budget; 1994 (Revised 2005). Available at <https://nces.ed.gov/FCSM/pdf/spwp22.pdf>.
9. McLaughlin C. Confidentiality protection in publicly released central cancer registry data. *Journal of Registry Management* 2002; 29(3):84–88.
10. Stoto M. *Statistical Issues in Interactive Web-Based Public Health Data Dissemination Systems*. Draft report prepared for the National Association of Public Health Statistics and Information Systems, Rand Corporation; September 2002.
11. Surveillance, Epidemiology, and End Results Program. *The SEER Program Code Manual*. 3rd ed. Bethesda, MD: National Cancer Institute, 1998.
12. Percy C, Van Holten V, Muir C (eds). *International Classification of Diseases for Oncology, 2nd edition*. Geneva, Switzerland: World Health Organization; 1990.
13. Hultstrom D, editor. *Standards for Cancer Registries, vol. II: Data Standards and Data Dictionary*, version 9.1, 6th ed. Springfield, IL: North American Association of Central Cancer Registries; 2001.
14. North American Association of Central Cancer Registries. *Standards for Cancer Registries, vol. III: Standards for Completeness, Quality, Analysis, and Management of Data*. Springfield, IL: North American Association of Central Cancer Registries; 2000.

15. Hutton MD, Simpson, LD, Miller DS, Weir HK, McDavid K, Hall HI, Progress toward nationwide cancer surveillance: an evaluation of the National Program of Cancer Registries, 1994–1999. *Journal of Registry Management* 2001;28(3):113–120.
16. Centers for Disease Control and Prevention. *U.S. Cancer Statistics Publication Criteria*. Available at: [https://www.cdc.gov/cancer/uscs/technical\\_notes/criteria/index.htm](https://www.cdc.gov/cancer/uscs/technical_notes/criteria/index.htm).
17. NAACCR Method to Estimate Completeness. A Data Analysis Tool for Calculations. Available at: <https://www.naacr.org/analysis-and-data-improvement-tools/#COMPLETENESS>.
18. Clegg LX, Fueur EJ, Midthune DN, Fay MP, Hankey BF. Impact of reporting delay and reporting error on cancer incidence rates and trends. *Journal of the National Cancer Institute* 2002; 94(20):1537–45.

**TABLE 1 –Comparison of the National Program of Cancer Registries-Cancer Surveillance System Datasets**

<b>Overview</b>						
	<b>Public Web-Based Query Systems</b>				<b>Analytic datasets</b>	
	<b>USCS Data Visualizations Tool</b>	<b>USCS WONDER<sup>a</sup></b>	<b>USCS Data for Partners<sup>b</sup></b>	<b>NCEH’S Tracking Network</b>	<b>USCS Public-Use Research Database</b>	<b>USCS Restricted-Access Dataset</b>
<b>Format</b>	Database of aggregate counts and rates, with text documentation	Database of aggregate counts and rates, with text documentation. The database behind the CDC firewall is case-specific microdata.	Database of aggregate counts and rates, with text documentation	Database of aggregate counts and rates, with text documentation. The database behind the CDC firewall is case-specific microdata.	Customized, analytic database. The database behind the SEER*Stat firewall is case-specific microdata with enforced cell suppression and case listing disabled.	Customized, analytic database available through proposal process
<b>Mode of Access</b>	Web-based query system with downloadable ASCII files	Web-based query system	Flat ASCII file, web-based query system, and separate brief text documentation	Web-based query system	SEER*Stat client-server mode only after receipt of signed Data Use Agreement	On-site at CDC or through CDC staff assistance
<b>Web Address or Contact Information</b>	USCS Web site <a href="http://www.cdc.gov/cancer/dataviz">www.cdc.gov/cancer/dataviz</a>	CDC WONDER <a href="http://wonder.cdc.gov">http://wonder.cdc.gov</a>	Request from <a href="mailto:uscdata@cdc.gov">uscdata@cdc.gov</a> (specify “USCS County” in subject line)	National Environmental Public Health Tracking Program <a href="https://ephtracking.cdc.gov/">https://ephtracking.cdc.gov/</a>	<a href="https://www.cdc.gov/cancer/public-use">https://www.cdc.gov/cancer/public-use</a>	Application process available at <a href="http://www.cdc.gov/rdc">www.cdc.gov/rdc</a>
<b>Contains Potentially Identifiable Information</b>	No		No	No	No	Yes
<b>Registry Eligibility Criteria for Data Completeness and Quality</b>	USCS publication criteria		USCS publication criteria; data meet criteria for unknown county	USCS publication criteria; data meet criteria for unknown county	USCS publication criteria	USCS publication criteria; data meet criteria for unknown county
<b>When Available</b>	Updated 2022		Updated 2022	Updated 2022	Updated 2022	Updated 2022

<sup>a</sup> This data file is also shared with OWH.

<sup>b</sup> This data file is shared with CDI and AHRQ.

**TABLE 1 – Comparison of the National Program of Cancer Registries-Cancer Surveillance System Datasets**

<b>Cases Included</b>						
	<b>Public Web-Based Query Systems</b>				<b>Analytic datasets</b>	
	<b>USCS Data Visualizations Tool</b>	<b>USCS WONDER</b>	<b>NPCR/SEER USCS County</b>	<b>NCEH’s Tracking Network</b>	<b>USCS Public-Use Research Database</b>	<b>USCS Restricted-Access Dataset</b>
<b>States/ Territories</b>	NPCR/SEER States meeting eligibility criteria		NPCR/SEER States meeting eligibility criteria	NPCR States meeting eligibility criteria	NPCR/SEER States meeting eligibility criteria	NPCR States meeting eligibility criteria
<b>Diagnosis Years</b>	1999; 2000; 2001; 2002; 2003; 2004; 2005; 2006; 2007; 2008; 2009; 2010; 2011; 2012; 2013; 2014; 2015; 2011-2015; 2016; 2017; 2018; 2019; 2020 preliminary results	1999; 2000; 2001; 2002; 2003; 2004; 2005; 2006; 2007; 2008; 2009; 2010; 2011; 2012; 2013; 2014; 2015; 2016; 2017; 2018; 2019	2015-2019	Individual years 2001 through 2019 for state level; 5-year increments for county level; 10-year increments for DCPC melanoma dashboard; 3-, 5-, 7- and 10-year increments for sub-county level	2001; 2002; 2003; 2004; 2005; 2006; 2007; 2008; 2009; 2010; 2011; 2012; 2013; 2014; 2015; 2016; 2017; 2018; 2019;	1999; 2000; 2001; 2002; 2003; 2004; 2005; 2006; 2007; 2008; 2009; 2010; 2011; 2012; 2013; 2014; 2015; 2016; 2017; 2018; 2019
<b>Cancer Sites</b>	All reportable invasive cancers; <i>in situ</i> female breast, <i>in situ</i> male and female breast, and benign and borderline primary intracranial and central nervous system tumors (diagnosis year 2004)		All reportable cancer sites combined; female breast; <i>in situ</i> female breast; cervix uteri; colon and rectum; lung and bronchus; melanoma; bladder; prostate; oral cavity and pharynx; brain and other nervous system; thyroid; kidney and renal pelvis; stomach; ovary; corpus and uterus, NOS; leukemias; non-Hodgkin lymphoma; liver and intrahepatic bile duct; pancreas, esophagus; and childhood cancers	Female breast; Late stage female breast; lung and bronchus; bladder; brain & other nervous system; thyroid; leukemias (all types; Acute myeloid leukemia; Chronic lymphocytic leukemia); non-Hodgkin lymphoma; all childhood cancers (state level only); childhood leukemias (state level only); childhood CNS & miscellaneous intracranial & intraspinal neoplasms (state level only); mesothelioma (state level only); kidney & renal pelvis; prostate; melanoma of skin; liver & intrahepatic bile duct; pancreas; oral cavity and pharynx; esophagus, larynx; testis, colon and rectum	All reportable invasive cancers; <i>in situ</i> female breast, and benign and borderline primary intracranial and central nervous system tumors (diagnosis year 2004)	All reportable invasive and <i>in situ</i> cancers and benign and borderline primary intracranial and central nervous system tumors (diagnosis year 2004)

**TABLE 1 – Comparison of the National Program of Cancer Registries-Cancer Surveillance System Datasets**

<b>Variables Included</b>						
	<b>Public Web-Based Query Systems</b>				<b>Analytic datasets</b>	
	<b>USCS Data Visualizations Tool</b>	<b>USCS WONDER</b>	<b>USCS Data for Partners</b>	<b>NCEH’s Tracking Network</b>	<b>USCS Public-Use Research Database</b>	<b>USCS Restricted-Access Dataset</b>
<b>Geographic Levels</b>	All areas combined; NPCR/SEER state, territory, congressional districts, county; SEER metropolitan area, IHS regions (AI/AN data only)	All areas combined; NPCR and SEER state or territory; county; region; MSA for cities of $\geq 500,000$ (additional levels may be added)	NPCR and SEER state or territory; county	NPCR state; county; sub-county (to include census tract, 5k, and 20k aggregations)	All areas combined; U.S. census region; NPCR and SEER state or territory	NPCR and SEER state or territory; county for approved requests only
<b>Race/Ethnicity</b>	All races combined; White; Black; Asian/Pacific Islander (API); American Indian/Alaska Native (AI/AN); Hispanic; White Hispanic; White non-Hispanic; Black Hispanic; Black non-Hispanic		All races combined; White; Black; AI/AN; API; Hispanic; White/Black Hispanic/non-Hispanic	All races combined; White; Black; AI/AN; API; Hispanic; White non-Hispanic; White-Hispanic. (Sub-county displayed for all races combined)	All races combined; White; Black; Asian/Pacific Islander (API); American Indian/Alaska Native (AI/AN); Hispanic; White Hispanic; White non-Hispanic; black Hispanic; Black non-Hispanic	All races reported; Hispanic; White Hispanic; White non-Hispanic; Black Hispanic; Black non-Hispanic
<b>Age Groups</b>	All ages combined and standard 5-year age groups for adults and <15, <20, and 5-year age groups for childhood cancers	All ages combined and standard 5-year age groups that can be combined by the user	Childhood cancers: <15 and <20; all other cancers: <50, 50–64, 65+	Childhood cancers: <15 and <20 Breast cancer: <50, 50+	All ages combined, standard 5-year age groups	Standard 5-year age groups and individual ages (Month and day of birth not provided for confidentiality reasons. If the age at diagnosis >99, then grouped into one category. Year of birth is also grouped.)
<b>Summary Stage</b>	Yes (Localized, Regional, Distant, and unknown/unstaged)	Yes	No	Yes (late stage screening amenable cancers)	Yes	Yes
<b>Histology</b>	International Classification of Childhood Cancers, Third Revision (all geographic areas combined), Mesothelioma (national and state level), Kaposi Sarcoma (national and state level), Consensus Conf on Cancer Registration of Brain, and CNS Tumors (all geographic areas combined)		No	No	Same as USCS Data Visualizations tool	Yes



**TABLE 1 – Comparison of the National Program of Cancer Registries-Cancer Surveillance System Datasets**

<b>Confidentiality Protection/Disclosure Limitation Measures Employed</b>						
	<b>Public Web-Based Query Systems</b>				<b>Analytic datasets</b>	
	<b>USCS Data Visualizations Tool</b>	<b>USCS WONDER</b>	<b>NPCR/SEER USCS County</b>	<b>Tracking Network</b>	<b>USCS Public-Use Research Database</b>	<b>USCS Restricted-Access Dataset</b>
<b>Direct or Record-Level Identifiers?</b>	No	No	No	No	No	Yes, but not in output which will be reviewed by CDC staff for confidentiality
<b>Aggregation</b>	Yes	Yes	Yes	Yes	No	No
<b>Limited Number of Variables</b>	Yes	Yes	Yes	Yes	Yes	Yes
<b>Grouping/Collapsing of Variables or Response Codes; e.g., race and age recode</b>	Yes	No	No	Yes	Yes	Yes
<b>(1) Average Annual Counts Rounded to the Nearest Whole Number</b> <b>(2) Average Annual Rates</b> <b>(3) Annual Averages Are Based on At Least 5 Years of Data</b>	No	Yes	Yes	Yes	No	No
<b>Cell Suppression</b>	Yes Counts and rates: count of <16	Yes Counts and rates: 5 year total count of <16	Yes Counts and unsmoothed rates: count of <16 or RSE > limit (25% for state and county-level, 30% for subcounty level) Smoothed rates: RSE > limit (25% for state and county-level, 30% for subcounty level)	Yes Counts and unsmoothed rates: count of <16 or RSE > limit (25% for state and county-level, 30% for subcounty level) Smoothed rates: RSE > limit (25% for state and county-level, 30% for subcounty level)	Yes Counts and rates: count of <16 enforced Case listing disabled	Yes (output reviewed by CDC analyst to ensure counts of <6 are suppressed)
<b>Complementary Cell Suppression</b>	As needed	As needed	As needed	As needed	As needed	As needed
<b>Public Release Disclosure Statement</b>	Yes	Yes	Yes	Yes	Yes	Yes
<b>Data Sharing Agreement and/or IRB Approval</b>	No	No	No	No	Yes	Yes
<b>User Authentication</b>	No	No	No	No	No	Yes
<b>Logging and Monitoring</b>	Limited	Limited	Limited	Limited	Yes, monitoring databases used, session type and date only	Yes

## APPENDIX A – State and Metro Area Cancer Registries

State, Metropolitan Area, and Territory Cancer Registries by Federal Funding Source, and First Diagnosis Year\* for Which Cancer Cases Were Reportable to CDC’s NPCR or NCI’s SEER Program

<b>State, Metropolitan Area, or Territory</b>	<b>First Diagnosis Year for Which Cancer Cases Were Reportable to NPCR or SEER*</b>	<b>Federal Funding Source</b>
Alabama	1996	NPCR
Alaska	1996	NPCR
Arizona	1995	NPCR
Arkansas	1996	NPCR
California	1995/2000	NPCR/SEER
Los Angeles	1992	SEER
San Francisco-Oakland	1973	SEER
San Jose-Monterey	1992	SEER
Colorado	1995	NPCR
Connecticut	1973	SEER
Delaware	1997	NPCR
District of Columbia	1996	NPCR
Florida	1995	NPCR
Georgia	1995/2010	NPCR/SEER
Atlanta	1975	SEER
Hawaii	1973	SEER
Idaho	1995/2018	NPCR/SEER
Illinois	1995/2022	NPCR/SEER
Indiana	1995	NPCR
Iowa	1973	SEER
Kansas	1995	NPCR
Kentucky	1995/2000	NPCR/SEER
Louisiana	1995/2000	NPCR/SEER
Maine	1995	NPCR
Maryland	1996	NPCR
Massachusetts	1995/2018	NPCR/SEER
Michigan	1995	NPCR
Detroit	1973	SEER
Minnesota	1995	NPCR
Mississippi	1996	NPCR
Missouri	1996	NPCR
Montana	1995	NPCR
Nebraska	1995	NPCR
Nevada	1995	NPCR

## APPENDIX A – State and Metro Area Cancer Registries

State, Metropolitan Area, and Territory Cancer Registries by Federal Funding Source, and First Diagnosis Year\* for Which Cancer Cases Were Reportable to CDC’s NPCR or NCI’s SEER Program

State, Metropolitan Area, or Territory	First Diagnosis Year for Which Cancer Cases Were Reportable to NPCR or SEER*	Federal Funding Source
New Hampshire	1995	NPCR
New Jersey	1995/2000	NPCR/SEER
New Mexico	1973	SEER
New York	1996/2018	NPCR/SEER
North Carolina	1995	NPCR
North Dakota	1997	NPCR
Ohio	1996	NPCR
Oklahoma	1997	NPCR
Oregon	1996	NPCR
Pennsylvania	1995	NPCR
Puerto Rico	1998	NPCR
Rhode Island	1995	NPCR
South Carolina	1996	NPCR
South Dakota	2000	NPCR
Tennessee	1999	NPCR
Texas	1995/2022	NPCR/SEER
U.S. Pacific Island Jurisdictions	2007	NPCR
Utah	1973/2016	SEER/NPCR
Vermont	1996	NPCR
Virginia	1996	NPCR
Virgin Islands	2016	NPCR
Washington	1995	NPCR
Seattle-Puget Sound	1974	SEER
West Virginia	1995	NPCR
Wisconsin**	1995	NPCR/SEER
Wyoming	1996	NPCR

\* Diagnosis year is the year during which a reported cancer case was first diagnosed.

\*\* Wisconsin receives research support from SEER but is not under contract to submit data.

CDC = Centers for Disease Control and Prevention

NCI = National Cancer Institute

NPCR = National Program of Cancer Registries

SEER = Surveillance, Epidemiology, and End Results Program

NPCR-CSS 2021 Data Release Policy

August 2021

1995–2020 Diagnosis Years

## **APPENDIX B – NPCR-CSS Overview of Data Security**

The NPCR-CSS project data reside on a dedicated server maintained by the NPCR-CSS contractor. To ensure the security and confidentiality of project data, the following provisions have been incorporated into the NPCR-CSS Security Plan in accordance with the requirements of the Assurance of Confidentiality.

The NPCR-CSS server is housed in a secure facility with a guard on duty 24 hours a day. Only authorized staff is allowed to access the facility. Support people are escorted by an authorized staff member if needed. The server resides on its own local area network (LAN) behind the NPCR-CSS contractor's firewall. NPCR-CSS contractor project staff access the server via VPN from their primary office location. Elevator and stairwell access is controlled by card key 24 hours. During business hours, an attendant is always present at the reception desk to guide visitors.

- Access to the NPCR-CSS server is limited to authorized NPCR-CSS contractor project staff. It is password-protected on its own security domain. No one, including NPCR-CSS contractor non-project staff, is allowed access to the NPCR-CSS data.
- All NPCR-CSS contractor project staff must sign a confidentiality agreement before passwords and keys are assigned. All staff must pass background checks appropriate to their responsibilities for a public trust position.
- NPCR-CSS data that are submitted electronically are encrypted during transmission from the States. They arrive on a document server behind the NPCR-CSS contractor's firewall. Each state has its own directory location so that no state has access to another state's data. The data are moved automatically from the document server to the NPCR-CSS server.
- Receipt and processing logs are maintained to document data receipt, file processing, and report production. All reports and electronic storage media containing NPCR-CSS data are stored under lock and key when not in use and will be destroyed once they are no longer needed.
- A comprehensive security plan has been developed by the NPCR-CSS contractor's security team. The security team consists of the Project Director, Project Manager, Systems Lead and Security Officer, Database Administrator and LAN/WAN Security Steward. All project staff receive annual security awareness training covering security procedures. The NPCR-CSS contractor's security team oversees operations to prevent unauthorized disclosure of the NPCR-CSS data.
- Periodic (currently quarterly, but no less than once per year) reviews and updates of the NPCR-CSS contractor's security processes will be conducted to adjust for rapid changes in computer technology and to incorporate advances in security approaches. The Security Plan will be amended as needed to maintain the continued security and confidentiality of NPCR-CSS data.

## APPENDIX C – Data Items for CBTRUS

The dataset for CBTRUS includes individual case-specific data from the NPCR-CSS dataset. The data items to be included are listed below.

*\*Diagnosis Years 1995-2003 invasive cases only, ≥2004 invasive, benign, and borderline cases*

Item Name	NAACCR Data Item Number	Comments
Patient ID (unique)	20	
NAACCR Record Version	50	
State of Residence at Diagnosis	80	
County at Diagnosis-Analysis	89	<i>Results presented as 5-year average annual rates as the smallest time period with &lt;16 cell and complementary cell suppression required</i>
Rural/Urban Continuum/Beale Code 2003	3310	
Rural/Urban Continuum/Beale Code 2013	3312	
NPCR Race Recode	Derived based on [160], [161], and [192]	<i>Same as race for USCS</i>
NHIAv2 Derived Hispanic Origin (Results of NAACCR Hispanic/Latino Identification Algorithm)	191	
NAPIIA	193	
Sex	220	
Age at Diagnosis	230	<i>Single year up to age 84; 85+ grouped into one category</i>
Sequence Number—Central	380	
Date of Diagnosis ( <i>YEAR portion only</i> )	390	<i>Day and month of diagnosis not requested</i>
Date of Diagnosis (full date)	390	<i>Full date</i>
Primary Site	400	
Laterality	410	
Grade	440	
Diagnostic Confirmation	490	
Type of Reporting Source	500	
Histologic Type (ICD-O-3)	522	
Behavior (ICD-O-3)	523	

## APPENDIX C – Data Items for CBTRUS

Item Name	NAACCR Data Item Number	Comments
SEER Summary Stage 1977	760	
SEER Summary Stage 2000	759	
Derived Summary Stage 2000	3020	
NPCR Cancer Stage		<i>Based on 759 and 3020</i>
RX Summ--Surgery Primary Site	1290	<i>≥2003 diagnosis years</i>
Reason for no surgery	1340	<i>≥2001 diagnosis years</i>
RX Summ—Radiation	1360	<i>≥2003 diagnosis years</i>
RX Summ--Chemo	1390	<i>2006-2011, ≥2015 diagnosis years</i>
RX Summ--BRM	1410	<i>Prior to 2006, reported as available</i>
Rad—Regional RX Modality	1570	<i>≥2003 diagnosis years</i>
Merged Radiation		<p><i>Based on 1360 and 1570</i></p> <p><i>1 = had radiation</i></p> <p><i>2 = did not have radiation</i></p> <p><i>3 = patient or guardian refused radiation</i></p> <p><i>4 = radiation recommended but unknown if received</i></p> <p><i>Applied only for selection below:</i>  <b>8000≤I522_HistTypeICDO3≤9049  </b>  <b>9056≤I522_HistTypeICDO3≤9139  </b>  <b>9141≤I522_HistTypeICDO3≤9589</b></p>
EDITS overrides	1990–2074	
CS Site-Specific Factor 1	2880	<i>WHO Grade</i>
Date of Last Contact	1750	<p><i>Diagnosis years 2001-2017 for states included in the NPCR RSA file.</i></p> <p><i>Cause of Death items (1910, 1914, 1915) are not included when review has determined that high quality COD information is not available for specific states.</i></p>
Vital Status	1760	
Vital Status Recode	1762	
Record Number Recode	1775	
Surv-Date Active Followup	1782	
Surv-Flag Active Followup	1783	
Survival Months Active Followup	1784	
Surv-Date Presumed Alive	1785	

## APPENDIX C – Data Items for CBTRUS

Item Name	NAACCR Data Item Number	Comments
Surv-Flag Presumed Alive	1786	
Survival Months Presumed Alive	1787	
Surv-Date Dx Recode	1788	
Follow-Up Source	1790	
Follow-Up Source Central	1791	
Cause of Death	1910	
SEER Cause-Specific COD	1914	
SEER Other COD	1915	
ICD Revision Number	1920	

## APPENDIX D – NPCR/SEER USCS Analytic Data Use Agreement

### U.S Cancer Statistics Analytic Data *Submitted [Month,Year] (diagnosis years 1998-xxxx)*

To protect the confidentiality of the individuals represented within the National Program of Cancer Registries – Cancer Surveillance System (NPCR-CSS) data, the Centers for Disease Control and Prevention (CDC) has obtained an Assurance of Confidentiality under Section 308(d) of the Public Health Service Act (42 U.S.C. 242m(d)), which provides that these data can only be used for the purpose for which they were obtained.

When using NPCR and U.S. Cancer Statistics analytic data for research purposes, it is necessary to ensure, to the extent possible, that use of the data will be limited to research or public health purposes. In accordance with applicable federal law, there must be no attempt to determine the identity of individuals represented by reported cases, or to use the information for any purpose other than for health statistical reporting and analysis.

CDC’s Division of Cancer Prevention and Control (DCPC) takes every possible measure to ensure that the identity of data subjects cannot be determined. All direct identifiers, as well as characteristics that might lead to identification of individuals, are omitted from the dataset. Certain demographic and clinical information has been included for research purposes; thus, all results must be presented or published in a manner that ensures that no individual can be identified. In addition, there must be no attempt to identify individuals from any computer file or to link with a computer file containing patient identifiers.

Data users must agree to the following provisions before to receiving access to U.S. Cancer Statistics Incidence, U.S. Cancer Statistics Delay Adjusted, NPCR Prevalence and/or NPCR Survival Analytic Data. ***Please initial after each statement to indicate agreement.***

***As the recipient of the U.S. Cancer Statistics Incidence (diagnosis years {year}-{year}), U.S. Cancer Statistics Delay Adjusted (diagnosis years {year}-{year}), NPCR Prevalence (diagnosis years {year}-{year}), and/or NPCR Survival Analytic Data (diagnosis years {year}-{year}):***

- I will adhere to the requirements of the Data Use Agreement and understand that my access to the data will be revoked if these requirements are violated. **Initials:** \_\_\_\_\_
- I understand that NPCR data belong to the states and territories. The states’ and territories’ agreement to use of the data are obtained through the activities outlined in the general NPCR-CSS Data Release Policy and by specific requests to the states and territories through the CSB management team. **Initials:** \_\_\_\_\_
- I will not use or permit others to use the datasets in any way other than for statistical reporting and analysis. **Initials:** \_\_\_\_\_
- I will not release or permit others to release the datasets or any part of them to any person except with DCPC’s written approval. **Initials:** \_\_\_\_\_
- I will not attempt to link or permit others to link the datasets with individually identifiable records from any other dataset without DCPC’s approval. **Initials:** \_\_\_\_\_



## APPENDIX D – NPCR/SEER USCS Analytic Data Use Agreement

- I will not access nor permit others to access (directly or remotely) the data outside the United States. **Initials:** \_\_\_\_\_
- I will not attempt to use the datasets or permit others to use them to learn the identity of any person or establishment included in any dataset. **Initials:** \_\_\_\_\_
- I will protect the data file(s) I receive with a password and/or encryption. In addition, any temporary or permanent analysis files, such as those produced with analytic software, will be protected in the same manner(s). **Initials:** \_\_\_\_\_
- I will take the following actions if the identity of any person or establishment is discovered inadvertently:
  - Make no use of this knowledge.
  - Notify DCPC’s Internal Data Users Groups by emailing [npcridug@cdc.gov](mailto:npcridug@cdc.gov).
  - As requested by DCPC, safeguard or destroy the information that identifies an individual or establishment
  - Inform no one else of the discovered identity. **Initials:** \_\_\_\_\_
- In addition, I will make every effort to release all statistical information in such a way as to avoid inadvertent disclosure. In order to do this:
  - I agree that all oral or written reports will contain only aggregate data and I will not report counts of fewer than 6 cases or statistics generated from fewer than 6 cases. **Initials:** \_\_\_\_\_
  - I understand that calculating rates or other statistics based on small numbers can raise statistical issues concerning stability and confidentiality. I will use appropriate caution when presenting and interpreting results based on fewer than 16 cases. **Initials:** \_\_\_\_\_
  - I will use complementary cell suppression to ensure that no data on an identifiable case can be derived through subtraction or other calculation from the combination of tables in all oral and written presentations. **Initials:** \_\_\_\_\_
- I have completed the [Assurance of Confidentiality Overview Course](#) available through HHS Learning Portal and have emailed my certificate of completion to [npcridug@cdc.gov](mailto:npcridug@cdc.gov). **Initials:** \_\_\_\_\_
- I have added my project to the NPCR Internal Analysis SharePoint table and, if applicable, I will notify and obtain permission from the Internal Data Users Group to analyze state- and county-level data. **Initials:** \_\_\_\_\_
- I will acknowledge central cancer registries whenever data are presented, released, or published by including the following (or similar) statement:

*These data were provided by central cancer registries participating in the National Program of Cancer Registries (NPCR) and submitted to CDC in November {year}, and/or the Surveillance, Epidemiology and End Results (SEER) program and submitted to NCI in November {year}. The U.S. Cancer Statistics Incidence Analytic dataset includes diagnosis years {year}–{year} (excluding*

**APPENDIX D – NPCR/SEER USCS Analytic Data Use Agreement**

*SEER-Metro Registry data); U.S. Cancer Statistics Delay Adjusted Analytic dataset includes diagnosis years {year}–{year} (excluding SEER-Metro Registry data), NPCR Prevalence Analytic dataset includes diagnosis years {year}–{year} and the NPCR Survival Analytic dataset includes diagnosis years {year}–{year}.*

**Initials:** \_\_\_\_\_

- As appropriate, I will cite the data:

*National Program of Cancer Registries SEER\*Stat Database: {Database file name} – {year}-{year}. United States Department of Health and Human Services, Centers for Disease Control and Prevention. Released {date}, based on the November {year} submission.*

**Initials:** \_\_\_\_\_

- I understand that if I require technical assistance in analyzing or interpreting the data and when such assistance goes beyond providing non-manipulated data, IDUG members reserves the right to request to be considered as a research collaborator or co-author in any resulting publications or presentations. **Initials:** \_\_\_\_\_
- I will provide a courtesy copy of papers or abstracts to the NPCR Internal Data Users Group at [npcridug@cdc.gov](mailto:npcridug@cdc.gov) as they are entered into Documentum for clearance. **Initials:** \_\_\_\_\_
- I am familiar with the use of **SEER\*Stat** in analyzing data or will complete the needed training. **Initials:** \_\_\_\_\_

***If you are requesting access to a U.S. Cancer Statistics database, you must first set-up [SEER Research Plus](#) access as the database includes SEER data.***

***After you have access to SEER Research Plus, complete the fields below, sign and date the agreement, and email all pages to [npcridug@cdc.gov](mailto:npcridug@cdc.gov).***

***The email address you provide must be the same one used during the SEER Research Plus verification process.***

**My signature below indicates that I agree to comply with all the above stated provisions.**

\_\_\_\_\_  
Signature Date

Name: \_\_\_\_\_

Title \_\_\_\_\_

Branch \_\_\_\_\_

Telephone \_\_\_\_\_ E-mail: \_\_\_\_\_

Please return all pages of the completed form to the NPCR Internal Data Users Group at [npcridug@cdc.gov](mailto:npcridug@cdc.gov).

## APPENDIX E – CDC Non-Disclosure Agreement

### NONDISCLOSURE AGREEMENT FOR DATA COVERED BY AN ASSURANCE OF CONFIDENTIALITY

*For use with CDC employees involved in activities with information covered by a Section 308(d) Assurance of Confidentiality*

The success of CDC's operations depends upon the voluntary cooperation of establishments, including States, and of persons who provide information requested by CDC programs under an assurance that such information will be kept confidential and be used only for epidemiological or statistical purposes.

When confidentiality is authorized, CDC operates under the restrictions of Section 308(d) of the Public Health Service Act (42 U.S.C. §242m(d)), which provides in summary that no information obtained in the course of its activities may be used for any purpose other than the purpose for which it was supplied, and that such information may not be published or released in a manner in which the establishment or person supplying the information or described in it is identifiable unless such establishment or person has consented. As a CDC employee granted access to information covered by Section 308(d), I understand and acknowledge that I am bound to comply with the restrictions provided to the information under Section 308(d).

I am aware that unauthorized disclosure of information covered by Section 308(d) of the Public Health Service Act may subject me to disciplinary action.

"I am aware that unauthorized disclosure of confidential information is punishable under Title 18, Section 1905 of the U.S. Code, which reads, in relevant part:

'Whoever, being an officer or employee of the United States or of any department or agency thereof...publishes, divulges, discloses, or makes known in any manner or to any extent not authorized by law any information coming to him in the course of his employment or official duties or by reason of any examination or investigation made by, or return, report or record made to or filed with, such department or agency or officer or employee thereof, which information concerns or relates to the trade secrets, processes, operations, style of work, or apparatus, or to the identity, confidential statistical data, amount or source of any income, profits, losses, or expenditures of any person, firm, partnership, corporation, or association; or permits any income return or copy thereof or any book containing any abstract or particulars thereof to be seen or examined by any person except as provided by law; shall be fined not more than \$1,000, or imprisoned not more than one year, or both; and shall be removed from office or employment.'

"I understand that unauthorized disclosure of confidential information is also punishable under the Privacy Act of 1974, Subsection 552a (i) (1), which reads:

'Any officer or employee of any agency, who by virtue of his employment or official position, has possession of, or access to, agency records which contain individually identifiable information the disclosure of which is prohibited by this section or by rules or regulations established thereunder, and who knowing that disclosure of the specific material is so prohibited,

**APPENDIX E – CDC Non-Disclosure Agreement**

willfully discloses the material in any manner to any person or agency not entitled to receive it, shall be guilty of a misdemeanor and fined not more than \$5,000.'

These provisions are consistent with and do not supersede, conflict with, or otherwise alter the employee obligations, rights, or liabilities created by existing statute or Executive order relating to (1) classified information, (2) communications to Congress, (3) the reporting to an Inspector General of a violation of any law, rule, or regulation, or mismanagement, a gross waste of funds, an abuse of authority, or a substantial and specific danger to public health or safety, or (4) any other whistleblower protection. The definitions, requirements, obligations, rights, sanctions, and liabilities created by controlling Executive orders and statutory provisions are incorporated into this agreement and are controlling.

**'My signature below indicates that I have read, understood, and agreed to comply with the above statements.**

---

Typed/Printed Name

Signature

Date

---

Center/Institute/Office

## APPENDIX E – CDC Non-Disclosure Agreement

### NON-EMPLOYEE 308(d) PLEDGE OF CONFIDENTIALITY

*For use when Non-Employees are provided access to data covered by a 308(d) Assurance of Confidentiality*

I, as a non-CDC Employee (e.g., Guest Researcher, Visiting Fellow, Student, Trainee, employee of a federal agency other than CDC, etc.) may be given access to information that is identifiable or potentially identifiable to a person and that is covered by Section 308(d) of the Public Health Service Act (42 U.S.C. §242m(d)), or an Assurance of Confidentiality. As a condition of this access, I am required to comply with the following safeguards for the protection of this covered data.

1. I agree to be bound by the following assurance:

In accordance with Section 308(d) of the Public Health Service Act (42 U.S.C. §242m(d)), I agree that no information obtained in the course of the activity described in the Assurance of Confidentiality will be used for any purpose other than the purpose for which it was supplied, unless I am informed in writing that such person has consented to its use for such other purposes. Further, I agree that no information obtained in the course of the activity described in the Assurance of Confidentiality will be disclosed in a manner in which the establishment or person supplying the information or described in it is identifiable, unless I am informed in writing that the establishment or person has consented to such disclosure, to anyone other than authorized staff of CDC or staff covered under this 308(d) Assurance.

2. I agree to maintain the following safeguards to assure that confidentiality is protected and to provide for the physical security of the records:

To preclude observation of confidential information by persons not authorized to have access to the information on the project, I shall maintain all records that I am provided access to that identify establishments or persons covered by this Assurance of Confidentiality or from which establishments or persons covered by this Assurance of Confidentiality could be identified in locked containers or protected computer files when not under immediate supervision by me or another authorized member of the project. The keys or means of access to these containers or files are not to be given to anyone other than those authorized to have access. I further agree to abide by any additional requirements imposed by CDC for safeguarding the identity of establishments or persons covered by this Assurance of Confidentiality.

My signature below indicates that I have carefully read and understand this agreement and the Assurance of Confidentiality, which pertains to the confidential nature of this project. As a(n) \_\_\_\_\_ (e.g., visiting scientist, guest researcher, fellow, trainee, employee of a federal agency other than CDC, etc.), I understand that I am prohibited from disclosing any such confidential information that has been obtained under this project to anyone

**APPENDIX E – CDC Non-Disclosure Agreement**

other than authorized staff of CDC or persons covered under this Section 308(d) Assurance of Confidentiality. I understand that any disclosure in violation of this Confidentiality Pledge may lead to termination of my employment, fellowship, training experience, or scientific collaboration, as well as other penalties.

---

Printed Name

---

Signature

---

Date

## **APPENDIX E – CDC Non-Disclosure Agreement**

### **Agreement of CDC Contractors for Safeguards Against Invasions of Privacy for Certain Establishments or Persons Covered by an Assurance of Confidentiality**

*For use where Contractors/Subcontracts have access to information covered by a 308(d) Assurance of Confidentiality*

Access to data covered by an Assurance of Confidentiality, titled Assurance of Confidentiality for the National Program of Cancer Registries Cancer Surveillance System, (“Assurance”) as provided by Section 308(d) of the Public Health Service Act (42 U.S.C. §242m(d)), is necessary for certain projects funded through contract task order number \_\_\_\_\_.

Consistent with Section 308(d), the contractor is required to give an assurance of confidentiality and to provide for safeguards to assure that confidentiality of the data covered by the Assurance is maintained.

To provide this assurance and these safeguards in performance of the contract, the contractor shall

1. Be bound by the following assurances:
  - a. No information that is identifiable or potentially identifiable to an establishment or person covered by the Assurance and obtained in the course of this activity may be used for any purpose other than the purpose for which it was supplied, unless CDC informs contractor in writing that such establishment or person has consented to its use for such other purposes.
  - b. No information that is identifiable or potentially identifiable to an establishment or person covered by the Assurance and obtained in the course of this activity may be disclosed to anyone other than authorized staff of CDC or others noted in the Assurance, unless CDC informs contractor in writing that such establishment or person has consented to its disclosure to such other persons.
  - c. No preliminary data from studies or projects that identifies or potentially identifies an establishment or person covered by the Assurance may be disclosed to anyone other than authorized staff of CDC or others noted in the Assurance of Confidentiality statement, unless this information is otherwise in the public domain or CDC has provided written permission for use of this information to be made public. For example, if CDC clears an abstract for a scientific presentation, this constitutes permission for public presentation.
  - d. New research study ideas that are not already funded through the above-referenced contract task order may be discussed or presented during calls/meetings as part of normal communications and coordination between CDC and the contractor; should these ideas lead to further activities with information covered by this Assurance, these protections will extend to those activities only if agreed to in writing by CDC.
2. Maintain the following safeguards to assure that the confidentiality provided by Section 308(d) and the Assurance is protected by the contractor and to provide for the physical security of the records:

**APPENDIX E – CDC Non-Disclosure Agreement**

- a. After having read the above Assurance, each employee of the contractor participating in this project is to sign the following pledge of confidentiality:

I have carefully read and understand the CDC assurance, which pertains to the confidential nature of identifiable or potentially identifiable data covered by the Assurance of Confidentiality to be handled in regard to these studies and reviewed as part of activities under task order \_\_\_\_\_. As an employee of the contractor, I understand that I am prohibited by law from disclosing any such confidential information that identifies or potentially identifies an establishment or person covered by the Assurance of Confidentiality, which has been obtained under the terms of this contract, to anyone other than authorized staff of CDC and that I may use this information only for the purposes for which it was obtained and consistent with the task order.

- b. To preclude observation of confidential information that identifies or potentially identifies an establishment or person covered by the Assurance by persons not employed on the project, the contractor shall maintain all confidential records that identify establishments or persons or from which establishments or persons could be identified under lock and key.

Specifically, at each site where these items are processed or maintained, all confidential records that will permit identification of establishments or persons are to be kept in locked containers when not in use by the contractor’s employees. The keys or means of access to these containers are to be held by a limited number of the contractor staff at each site. When confidential records that will permit identification of establishments or persons are being used in a room, admittance to the room is to be restricted to employees pledged to confidentiality and employed on this project. If at any time the contractor’s employees are absent from the room, it is to be locked.

- c. The contractor and his professional staff will take steps to insure that the intent of the pledge of confidentiality is enforced at all times through appropriate qualifications standards for all personnel working on this project and through adequate training and periodic follow-up procedures.

- 3. Flow down all requirements set forth in this Agreement to all subcontracts and all subcontract employees.

\_\_\_\_\_  
(Typed/printed Name)

\_\_\_\_\_  
(Signature)

\_\_\_\_\_  
(Date)



## APPENDIX E – CDC Non-Disclosure Agreement

### CONFIDENTIALITY AGREEMENT

for

**Access to Information Technology Resources at the  
Centers for Disease Control and Prevention**

and

**Limitation on Disclosure of Sensitive Information Under  
Contract No. \_\_\_\_\_, Task Order \_\_\_\_\_**

As an employee or subcontractor of \_\_\_\_\_, **THE PARTICIPANT** requires a wide range of access to confidential information and Federal information technology (IT) resources and information maintained by the Centers for Disease Control and Prevention, (CDC), an agency of the U.S. Department of Health and Human Services.

In consideration for the following mutual covenants, the parties agree as follows:

1. Within the context of CDC Contract No. \_\_\_\_\_, Task Order \_\_\_\_\_, and in accordance with the terms of this agreement, **CDC** grants limited access to the following:
  - a. The Federal information technology (IT) resources generally described in Table 1.
  - b. Datasets and/or public use data tapes derived from information collected under an Assurance of Confidentiality authorized by Section 308(d) of the Public Health Service Act, also listed in Table 1.
2. **THE PARTICIPANT** acknowledges that within the CDC environment, a variety of restricted access information is held, the vast bulk of which is categorized as “Sensitive but Unclassified”, and that in the performance of CDC Contract No. \_\_\_\_\_, Task Order \_\_\_\_\_, the participant may require access to such limited access information. Categories of limited access information include the following:

Health & health-related data on individuals, groups, entities, some of which identify individuals

Federal Privacy Act “systems of records”

Information exempted from release under Freedom of Information Act

Proprietary data

National Defense-related information

Information subject to contractual restrictions on access

Information covered by a Certificate or Assurance of Confidentiality [P.H.S. Act, Sects. 301(d) & 308(d)]

**NPCR-CSS 2021 Data Release Policy**

**August 2021**

**1995–2020 Diagnosis Years**

## APPENDIX E – CDC Non-Disclosure Agreement

Data collected under other specific legislative mandates (i.e. tobacco, transfer of biological, etc.)

Data identified as pre-release, internal working papers, etc., of federal agency

Therefore, **THE PARTICIPANT** further agrees to not attempt to identify any person contained in contract data and to make no use of the identity of any person or establishment discovered inadvertently and advise **CDC** of any such discovery.

3. **THE PARTICIPANT** acknowledges the sensitive and confidential nature of the information covered by this agreement and agrees to employ all reasonable efforts to maintain such information secret and confidential, such efforts to be no less than the degree of care employed by ICF Incorporated to preserve and safeguard ICF Incorporated's own information.
4. **THE PARTICIPANT** agrees to utilize any information accessed through the performance of CDC Contract No. \_\_\_\_\_, Task Order \_\_\_\_\_ solely for the purpose of performing that Contract;
5. **THE PARTICIPANT** has read and agrees to be bound by CDC policies and standards regarding confidentiality and use of Federal IT resources. Further, **THE PARTICIPANT** agrees to attend one hour of training by **CDC** on information security and the use of IT resources at **CDC**.
6. **THE PARTICIPANT** agrees to refrain from any of the following prohibited uses:
  - a. Disclosing, revealing, or giving to anyone information accessed under CDC Contract No. \_\_\_\_\_, Task Order \_\_\_\_\_ except to employees of ICF Incorporated who have a need for the information and who are bound to it by like obligation as to confidentiality, without the express written permission of **CDC**.
  - b. Attempting to override or avoid security and integrity procedures and devices established by **CDC**, or its components, to control access to federal IT resources.
  - c. Attempting to override or avoid security and integrity procedures and devices established by outside organizations to control access to their information systems and IT resources.
  - d. Using hardware and/or software or downloading software within the scope of the project that is not specifically authorized in writing by the Project Officer.
  - e. Violating copyrights or software licensing agreements.
  - f. Using **CDC**'s name or logos to misrepresent, as falling under **CDC** auspices, personal materials, or materials one produces on behalf of an approved group.

## APPENDIX E – CDC Non-Disclosure Agreement

7. Upon expiration of this Agreement or CDC Contract No. \_\_\_\_\_, Task Order \_\_\_\_\_, **THE PARTICIPANT** agrees to destroy or return to CDC any information accessed through the performance of contract that falls under one or more of the categories listed under paragraph 2 above and that was copied, printed, or otherwise duplicated.
8. **CDC** has the capability and the authority to audit its federal IT resources, and under appropriate circumstances, monitor their use.
9. **CDC** may terminate this access with or without cause at any time without advance notice.
10. **THE PARTICIPANT'S** authorized access automatically expires at the end of the contract period, or sooner if so indicated in the space at the top of Table 1. A written renewal request must be submitted *two months* prior to the termination, with appropriate justification for each access to be continued. A new Agreement for Access and Limitation on Disclosure is required for each renewal.
11. The construction, interpretation, and performance of this Agreement shall be governed by U.S. Federal law.

Violations of this agreement or misuse of CDC's federal IT resources may subject **THE PARTICIPANT** to criminal penalties in accordance with Federal law (attached). In addition, **THE PARTICIPANT** understands that other Federal laws and regulations govern CDC's maintenance and operation of these Federal IT resources and may apply to **THE PARTICIPANT**.

**APPENDIX E – CDC Non-Disclosure Agreement**

12. I have read, understood, and agree to comply with the above statements.

\_\_\_\_\_  
*Print Name: Last, First, MI (Person Requesting Access)*

\_\_\_\_\_  
*Print Name: Last, First, MI (Contractor's Official Witness)*

\_\_\_\_\_  
**Current Position**

\_\_\_\_\_  
**Position**

\_\_\_\_\_  
**Signature**

\_\_\_\_\_  
**Signature**

\_\_\_\_\_  
*Date: (mm/dd/yyyy)*

\_\_\_\_\_  
*Date: (mm/dd/yyyy)*

**CDC Point of Contact (Technical Monitor or Project Officer):**

\_\_\_\_\_  
*Print Name: Last, First, MI*

\_\_\_\_\_  
*Position*

\_\_\_\_\_  
*Signature*

\_\_\_\_\_  
*Date: (mm/dd/yyyy)*

Copies of the following CDC Policy statements are to be provided to each person requesting access.

**APPENDIX E – CDC Non-Disclosure Agreement**

Laws, Policies and Procedures Governing Use of Electronic Mail, Intranet, Internet and Other Information Technology (IT) ADP Security Policy (Manual Guide-Information Resources Management, No. CDC-3, 3/15/89) 18 U.S.C. Sections 641 and 1030.

**Table 1  
Federal Information Resources  
Authorized**

<b>Federal IT Resource Name or Description</b>	<b>Location</b>	<b>Authorizing Official(s)</b>
Main point of entry to CDC IT resources: Information Resources Management Office		None authorized
Other LAN account(s)		None authorized
CDC mainframe account		None authorized
CDC e-mail account		None authorized
Internet access		None authorized
CDC Intranet access		None authorized
Cancer incidence data from awardees funded by CDC’s Program Announcement DP17-1701 for a cooperative agreement under for the National Program of Cancer Registries		CDC Contracting Officer’s Representative CDC Project Officer
Mortality data from the National Center for Health Statistics (NCHS) <sup>1</sup>		NCHS
Population data from the U.S. Census Bureau		Data publicly available on Internet

<sup>1</sup>By signing this agreement, THE PARTICIPANT agrees to abide by the conditions stipulated by NCHS in the NCHS Data Use Agreement.

Access to a specific resource does not imply access to any other resource.

## APPENDIX E – CDC Non-Disclosure Agreement

### Appendix 1

Access to additional resources may be granted upon written request, as described below.

A written request shall be provided to \_\_\_\_\_, who will forward the request with a statement of support of the justification provided, to \_\_\_\_\_, the CDC Contracting Officer's Representative (COR) for Contract No. \_\_\_\_\_, Task Order \_\_\_\_\_ in the \_\_\_\_\_ Branch, Center for Disease Control and Prevention (CDC).

If the requested access involves a physically separate or limited access device or dataset, the appropriate steward of that device or dataset shall be provided with a copy of the request for review and authorization.

Upon acceptance of the request by all appropriate parties, an amendment to the Agreement for Access and Limitation on Disclosure will be executed, and a copy of any appropriate limitations on access and use will be provided. When this has been done, access will be provided.

If effective access not contained in table 1 is recognized, or if another relationship is established with a CDC organization that may lead to additional access to federal IT resources at CDC, written notice of such shall be provided to \_\_\_\_\_, and \_\_\_\_\_, the CDC COR for Contract No. \_\_\_\_\_, Task Order \_\_\_\_\_ Branch, Center for Disease Control and Prevention (CDC).

## APPENDIX F – Data Items for NPCR/SEER USCS Incidence Analytic Dataset

SEER*Stat Category	SEER*Stat Variable Name	Restrictions
Age at Diagnosis	Age recode with <1 year olds	
Race, Sex, Year Dx, Registry, County	Sex	
	Year of diagnosis	
	Addr at DX – state	
	*County at DX Analysis	KS and MN data unavailable
	*State-county	KS and MN data unavailable
	USCS standard	
	USCS9819	
	USCS9919	
	USCS1019	
	USCS1519	
	Race recode for USCS	
	Program	
	*Econ status	
	*Region/Division	
	Region	
Origin recode NHIA (Hispanic, Non-Hisp)		
Site and Morphology	Primary Site – labeled	
	*Primary Site	
	Histologic Type ICD-O-3	
	*Behavior Code ICD-O-3	
	Grade	
	Grade clinical	
	Grade pathological	
	Grade post therapy	
	Diagnostic confirmation	
	ICD-O-3 Hist/behavior, labeled	
	*ICD-O-3 Hist/behavior, malig, labeled	
	Site recode ICD-O-3/WHO 2008	
	ICCC site recode ICD-O-3/WHO 2008	
	ICCC site rec extended ICD-O-3/WHO 2008	
	AYA site recode 2020	
Lymphoid neoplasm recode 2021 revision		
Behavior recode for analysis derived/WHO2008		
Stage – LRD [Summary and Historic]	*Derived SS2000	
	*SEER Summary Stage 2000	
	*SEER Summary Stage 1977	
	*SEER Summary Stage 2018	
	Merged Summary Stage	
Therapy	*RX summ – surg prim site	Diagnosis years ≥2003

## APPENDIX F – Data Items for NPCR/SEER USCS Analytic Dataset

	*RX summ – chemo	Female and male breast only, diagnosis years $\geq 2003$ , and NPCR CCRs <sup>†</sup> only
	Phase I Radiation Treatment Modality	Female & male breast and colorectal only, diagnosis years $\geq 2018$
	*Merged radiation	Female & male breast and colorectal only, diagnosis years $\geq 2003$ , and NPCR CCRs only
Extent of Disease – CS	*CS site-specific factor 1	Brain & other CNS and diagnosis years 2011-2017
		-
	Merged estrogen receptor	Female and male breast only and diagnosis years $\geq 2004$
	Merged progesterone receptor	Female and male breast only and diagnosis years $\geq 2004$
	Merged HER2 receptor	Female and male breast only and diagnosis years $\geq 2010$
	Laterality	
Multiple Primary Fields	Sequence number - central	
Race and Age (case data only)	Age at Diagnosis	
	Race 1	
	*IHS Link	
Geographic Locations	Ruralurban continuum 2013	
	*Census Tract Poverty Indicator	Diagnosis years $\geq 2014$ , NPCR CCRs only
Dates	Year of Birth	
	Month of diagnosis	
Other	Type of Reporting Source	
Merged System-Supplied	Alcohol-related cancers	
	HPV-related cancers	
	Obesity-related cancers	
	Physical inactivity-related cancers	
	Tobacco-related cancers	
	State race eth suppress	

\* Variable is only available in the internal incidence database; it is not available in the NPCR/SEER U.S. Cancer Statistics Public Use Database



## APPENDIX G – Data Items for NPCR Internal Survival Dataset

SEER*Stat Category	SEER*Stat Variable Name	Restrictions
Age at Diagnosis	Age recode with single ages and 85+	
Race, Sex, Year Dx, Registry, County	Sex	
	Year of diagnosis	
	Addr at DX – state	
	County at DX Analysis	
	State-county	
	Rural-urban continuum 2013	
	NPCR project flag	
	Economic status	
	Race and origin recode (NHW, NHB, NHAIAN, NHAPI, Hispanic)	
Race recode (White, Black, Other)		
Site and Morphology	Primary Site – labeled	
	Histologic Type ICD-O-3	
	Behavior Code ICD-O-3	
	Grade	
	Diagnostic confirmation	
	ICD-O-3-Hist/behavior, labeled	
	ICD-O-3-Hist/behavior, malig, labeled	
	Site recode ICD-O-3/WHO 2008	
	ICCC site recode ICD-O-3/WHO 2008	
	Behavior recode for analysis derived/WHO2008	
Stage – LRD [Summary and Historic]	Derived SS2000	
	SEER Summary Stage 2000	
	Merged Summary Stage 2000	
Therapy	*RX summ – surg prim site	Diagnosis years ≥2003
	*Merged radiation	Female breast and colorectal only, diagnosis years ≥2003, and NPCR CCRs only
Extent of Disease – CS	CS Site-Specific Factor 1	Brain/CNS and diagnosis years 2011-2017
	Merged estrogen receptor	Female and male breast only and diagnosis years ≥2004
	Merged progesterone receptor	Female and male breast only and diagnosis years ≥2004
	Merged HER2 receptor	Female and male breast only and diagnosis years ≥2010
	Laterality	
Cause of Death (COD) and Follow-up	Survival months – presumed alive	
	Survival months flag – presumed alive	

## APPENDIX G – Data Items for NPCR Internal Survival Dataset

SEER*Stat Category	SEER*Stat Variable Name	Restrictions
	Cause of death (ICD-10)	
	ICD revision number	
	Vital status	
	Follow-up source central	
	COD exclusion flag	
	Original vital status	
	Vital status recode (study cutoff used)	
	Cause of death recode	
	COD recode with Kaposi and mesothelioma	
Multiple Primary Fields	Sequence number - central	
Race and Age (case data only)	Age at Diagnosis	
	Race 1	
	NHIA derived Hispanic origin	
	Age recode with <1 year olds	
Dates	Presumed alive year of last contact recode	
	Presumed alive month of last contact recode	
	Presumed alive day of last contact recode	
	Year of birth	
	Month of diagnosis	
	Day of diagnosis	
	Original day of last contact	
	Original month of last contact	
	Original year of last contact	
	Original year of diagnosis	
	Original day of diagnosis	
	Original month of diagnosis	
Other	Type of Reporting Source	
User-Specified	EDPMDE LinkVar	

## **APPENDIX H – NPCR-CSS 308(d) Assurance of Confidentiality Statement**

A public health surveillance system of population-based cancer incidence data received from cooperative agreement holders for the National Program of Cancer Registries is being conducted by the National Center for Chronic Disease Prevention and Health Promotion (NCCDPHP) of the Centers for Disease Control and Prevention (CDC), an agency of the U.S. Department of Health and Human Services, and ICF Incorporated, a contractor of CDC. The information to be received by CDC is a subset of a standard set of data items that the state central cancer registry routinely receives from hospitals, pathology labs, clinics, private physicians, and other mandated reporters on all cancer cases diagnosed in the state. This information includes patient demographics and cancer diagnosis, treatment, and outcome data.

Each year, CDC requests cumulative data from central cancer registries. The variables reported to CDC may vary from year to year. The data submitted to CDC do not contain any direct identifiers, such as name or Social Security Number. Though project data do not contain direct identifiers, CCRS do report indirect identifiers such as patient demographic data items (e.g., a unique identifier, birth date, sex, race, ethnicity, birth place, county of residence, census tract, zipcode) and information about the type of cancer (e.g., date of diagnosis, stage at diagnosis, treatment). The cancer registries maintain these data permanently in longitudinal databases that are used for public health surveillance, program planning and evaluation, and data analyses. CDC updates its longitudinal database each year with data received from central cancer registries. NCCDPHP, recognizing the sensitivity of the data being furnished by the states, has applied for and obtained an Assurance of Confidentiality to provide a greater level of protection for the data while at CDC and at the contractor site.

Individual record-level data received by CDC or its contractors as part of this public health surveillance system that could lead to direct or indirect identification of cancer patients is collected and maintained at CDC under Section 306 of the Public Health Service (PHS) Act (42 U.S.C. 242k) with an assurance that it will be held in strict confidence in accordance with Section 308(d) of the PHS Act (42 U.S.C. 242m). It is used only for purposes stated in this assurance and are not otherwise disclosed or released, even following the death of cancer patients in this surveillance system. These data are used by CDC scientists for routine cancer surveillance, program planning and evaluation, and to provide data for cancer-related research questions that support the purpose of this public health surveillance program, e.g., monitoring the frequency and distribution of disease, evaluating cancer prevention and control activities, program planning and evaluation.

Researchers within CDC, including contract employees and qualified organizations, will be able to access individual, record-level data (i.e., data that do not directly identify individuals but that could lead to identification when combined with other information) for legitimate cancer-related research questions and reporting purposes through the full NPCR CSS analytic dataset, a less restricted dataset with information not included in the restricted-access datasets but one that does not contain all data submitted by the CCRs. A separate complete dataset (i.e., all information submitted by the CCRs) is available for data quality assessments only. “Qualified organizations” are defined as organizations with staff qualified to undertake the proposed analyses by means of specific academic training or demonstrable, related experience in cancer epidemiologic, medical,

## **APPENDIX H – NPCR-CSS 308(d) Assurance of Confidentiality Statement**

biomedical, or statistical research and the organization is identified in the NPCR CSS Data Release Policy. These individuals and organizations will be required to adhere to a strict security and confidentiality protocol.

Restricted access will be provided to researchers outside of the CDC, its contractors, or qualified organizations through the National Center for Health Statistics Research Data Centers (NCHS RDC) or, in limited instances, an aggregated data file for federal and trusted partners. A restricted-access dataset is defined as the version of the full NPCR CSS analytic dataset, either aggregated data or individual, record-level data that have been modified as needed to minimize the potential for disclosure of confidential information. For restricted-access datasets, some variables such as county at diagnosis will only be released in a modified format. The unique identifying number assigned to each individual by the central cancer registry is replaced by a random number assigned at CDC to reduce the possibility of linkage to other state- or territory-level files with indirect identifiers. This restricted access will be controlled in such a way as to limit the researchers' ability to publish or otherwise provide others access to data that could lead to identification of an individual (i.e., small numbers of cases, unique cancer types in a small geographic area, or aggregated in a way that a case could be identified).

Information collected by CDC is used without personal identifiers for publication in statistical and analytic summaries and for release in restricted release datasets for research. Information that could lead to direct or indirect identification of cancer patients is not made available to any group or individual that have not met the qualifications established by CDC and are not described in the NPCR CSS Data Release Policy. In particular, such information is not disclosed to insurance companies, any party involved in civil, criminal, or administrative litigation, agencies of federal, state, or local government, or any other member of the public.

Collected information that could lead to direct or indirect identification of cancer patients is kept confidential and—with the exception of CDC employees, their contractors, and qualified researchers—no one is allowed to see or have access to the information. CDC employees and contractors are required to handle the information in accordance with principles outlined in the CDC Staff Manual on Confidentiality and to follow the specific procedures documented in the Confidentiality Security Statement for this project. Qualified researchers are required to sign the NCHS RDC data sharing agreements and abide by the NCHS RDC confidentiality procedures. Access to data released through public-use datasets requires the user to complete and return a signed data use agreement acknowledging confidentiality requirements. Qualified organizations (e.g., the North American Association of Central Cancer Registries, American Cancer Society, National Cancer Institute, and the Central Brain Tumor Registry of the United States) are required to sign a detailed data release agreement to have access to restricted release data.

## **APPENDIX I – NPCR-CSS 308(d) Assurance of Confidentiality FAQ**

### **Background**

The Centers for Disease Control and Prevention (CDC) is responsible for public health surveillance in the United States. CDC collects, compiles, and publishes a large volume of personal, medical, epidemiologic, and statistical data. The success of CDC's operations depends, in part, on the agency's ability to protect the confidentiality of these data. While it is a matter of principle for CDC to guard sensitive information and federal statutes such as the Privacy Act of 1974 provide a degree of protection for personally identifiable data, Section 308(d) of the Public Health Service Act (42 U.S.C. 242m(d)) enables CDC to provide the highest level of confidentiality protection for sensitive and mission-significant research and surveillance data.

CDC received a formal delegation of authority from the National Center for Health Statistics (NCHS) (formally a separate agency) to grant 308(d) confidentiality protection in 1983. Section 308(d) of the Public Health Service Act ensures the confidentiality of data collected under Sections 304 and 306 of the Public Health Service Act. These special legislative authorities were the provisions under which NCHS collects and safeguards most of its survey data, along with the mortality data within the National Death Index. CDC was required to establish a stringent application process and continues to use the authority sparingly. The agency has granted confidentiality assurances to projects deemed significant to CDC's mission, such as surveillance of hospital infections, AIDS and HIV infections, pregnancy-related mortality, and congenital defects. Fewer than 65 projects have received 308(d) protection since CDC received this authority, and currently there are approximately 20-5 active projects with 308(d) confidentiality assurances. As a testament to the importance of this project to the mission of CDC, the National Program of Cancer Registries (NPCR) has been afforded this special data protection.

### **What is stated in Public Health Service Act, Section 308(d)?**

The first clause of Section 308(d) states that CDC must explain the purpose for collecting data to persons or agencies supplying information, and it guarantees that CDC will be limited to those specified uses unless an additional consent is obtained. Moreover, the information obtained may be used only by CDC staff or CDC's contractors in the pursuit of such stated purposes. The second clause states that CDC may never release identifiable information without the advance, explicit approval of the person or establishment supplying the information or by the person or establishment described in the information.

### **What process did NPCR undertake to obtain 308(d) confidentiality protection?**

NPCR staff worked with the CDC Office of General Counsel and the CDC Confidentiality and Privacy Officer to prepare the application for the NPCR Cancer Surveillance System (CSS) project. The application contained the following four components:

- A Justification Statement summarizing the NPCR-CSS project's programmatic purpose, the type of data to be collected, and the uses to be made of the information. This statement also included an assurance that a) the requested data would not be furnished without the guarantee of a confidentiality assurance, b) confidentiality assurance is important to protect the individuals described in the data and to reassure the institutions

## **APPENDIX I – NPCR-CSS 308(d) Assurance of Confidentiality FAQ**

submitting data, c) the information cannot reliably be obtained from other sources, d) the information is essential to the project's success, e) granting the confidentiality assurance would not prohibit CDC from fulfilling its responsibilities, and f) the advantages of assuring confidentiality outweigh the disadvantages.

- An Assurance of Confidentiality Statement delineating anticipated data uses and those with whom identifiable data would be shared, along with general advisements regarding the confidentiality protection.
- A Confidentiality Security Statement detailing the stringent safeguarding measures in place to ensure that the promise of confidentiality would not be jeopardized by practices of staff handling the data.
- An Institutional Review Board (IRB) Review Status Statement verifying NPCR-CSS's exemption from CDC IRB approval. (The Human Subjects Administrator at the National Center for Chronic Disease Prevention and Health Promotion determined that NPCR-CSS activities are routine surveillance and not research on human subjects. Therefore, protocol review by CDC IRB was deemed unnecessary.)

The application was submitted to the CDC Confidentiality Officer for review and modification, prepared for presentation to the CDC Confidentiality Review Group (CRG), and in May 2000 NPCR received 308(d) confidentiality protection approval for NPCR-CSS data, including authorization for retroactive confidentiality protection beginning with diagnosis year 1995. NPCR must file for continuation every 5 years to maintain the assurance.

### **What makes 308(d) confidentiality assurance the best protection for NPCR-CSS data?**

The 308(d) confidentiality assurance is the only confidentiality protection that covers routine surveillance activities, such as those conducted by NPCR-CSS. The assurance specifies that data protected by 308(d) may be used only for statistical or epidemiological purposes and not released further in identifiable form without consent. Another exclusive advantage of 308(d) is that it also protects indirectly identifiable data. Operationally, this means that NPCR may never release a directly identifiable variable (e.g., Social Security number) or any combination of variables that could be used to indirectly identify an individual. Finally, 308(d) provides protection for information on both living and deceased individuals.

### **Are there any disadvantages to individuals or institutions protected by the 308(d) confidentiality assurances?**

A 308(d) confidentiality assurance does not pose a disadvantage for individuals or institutions submitting data to CDC. In fact, 308(d) provides an added benefit because it prevents CDC from freely releasing data to researchers and any other persons or entities that could request access to the data. With the confidentiality assurance protecting NPCR-CSS data, NPCR staff members are prohibited from sharing data except for the purposes stated at the time of data collection, unless consent from those who provided the assurance is obtained.

### **Does NPCR's 308(d) confidentiality assurance protect the data from subpoena and Freedom of Information Act (FOIA) requests?**

## **APPENDIX I – NPCR-CSS 308(d) Assurance of Confidentiality FAQ**

The 308(d) assurance is the strongest protection against compulsory legal disclosure that CDC can offer. Although CDC receives FOIA requests, the FOIA (b)(6) exemption enables CDC to withhold sensitive, individually identified data that would constitute a “clearly unwarranted invasion of personal privacy.” It is CDC’s firm position that all projects covered by a 308(d) confidentiality assurance, including NPCR-CSS, meet this exemption.

### **Has a case involving 308(d) been tested in court?**

Yes. CDC’s ability to protect data submitted to the agency was upheld in court. The case involved a National Institute for Occupational Safety and Health project collecting death certificate information, which is widely accepted as the least sensitive data protected by 308(d). The court’s ruling in favor of the non-release of these data establishes an effective precedent for restricting access to more sensitive data, such as that collected by a cancer registry.

### **How long are confidential data submitted to NPCR-CSS protected?**

NPCR-CSS data are covered by the 308(d) confidentiality assurance forever. Individual records in the NPCR-CSS surveillance system are protected even following the death of the cancer patients.

### **Will NPCR release CSS data to persons or agencies outside of CDC?**

An assurance of confidentiality protects NPCR-CSS data held at CDC and by its contractor. The 308(d) confidentiality protection does not go with the data whether released publicly or through restricted means, and any data released to qualified researchers by CDC are subject to the limits of any coverage afforded by the requesting agency. However, it is important to note that NPCR’s confidentiality assurance prohibits the release of any data that are directly or indirectly identifiable. Therefore, CDC would not release highly sensitive NPCR-CSS data. Restricted access data that are released to external researchers are done so in accordance with the NCHS RDC proposal process and confidentiality procedures, prohibiting attempts to identify subjects within the record system. Under the 308(d), NPCR is permitted to release NPCR-CSS data to qualified researchers and organizations, such as the North American Association of Central Cancer Registries (NAACCR), American Cancer Society (ACS), and National Cancer Institute (NCI). This is so because these entities were specifically mentioned in the NPCR-CSS confidentiality assurance as anticipated recipients of identifiable data. Prior to the restricted release of NPCR-CSS data to qualified organizations, a detailed data use agreement must be signed by the requesting party (attachment I). Information that could lead to the identification of cancer patients, through direct or indirect methods, cannot be made available to any other group or individual. In particular, NPCR cannot disclose information to insurance companies; any party involved in civil, criminal, or administrative litigation; agencies of federal, state, or local government; or any other member of the public.

### **Are there penalties for violating the confidentiality assurance?**

NPCR employees and NPCR-CSS contractor staff working on the NPCR-CSS project may be subject to fine, imprisonment, and termination of employment for unauthorized disclosure of confidential information. To assure that all NPCR employees are aware of their responsibilities to maintain and protect NPCR-CSS records and the penalties for failing to comply, CDC employees must read and sign a data use agreement. Contract employees with access to NPCR-CSS data are required to sign a confidentiality agreement.

## APPENDIX J – Data Items for NPCR/SEER USCS Incidence Public Use Research Dataset

The research use NPCR/SEER USCS Incidence Public Use dataset contains individual case-specific data from the USCS dataset with enforced <16 cell suppression and case listing disabled.

SEER*Stat Category	SEER*Stat Variable Name	Restrictions
Age at Diagnosis	Age recode with <1 year olds	
Race, Sex, Year Dx, Registry	Sex	
	Year of diagnosis	
	Addr at DX – state	
	USCS standard	
	Race recode for USCS	
	Program	
	Region	
	USCS0119	
	USCS1019	
	USCS1519	
Site and Morphology	Origin recode NHIA (Hispanic, Non-Hisp)	
	Primary site – labeled	
	Histologic type ICD-O-3	
	Grade	
	Grade clinical	
	Grade pathological	
	Diagnostic confirmation	
	ICD-O-3 hist/behavior, labeled	
	Site recode ICD-O-3/WHO 2008	
	ICCC site recode ICD-O-3/WHO 2008	
	ICCC site rec extended ICD-O-3/WHO 2008	
	AYA site recode 2020	
Lymphoid neoplasm recode 2021 revision		
Behavior ICD-O-3		
Stage – LRD [Summary and Historic]	Merged summary stage 2000	
Therapy	RX summ – surg prim site	Female breast only and diagnosis years ≥2003
Extent of Disease – CS	CS site-specific factor 1	Brain & other CNS and diagnosis years 2011-2017
	Merged estrogen receptor	Female and male breast only and diagnosis years ≥2004
	Merged progesterone receptor	Female and male breast only and diagnosis years ≥2004
	Merged HER2 receptor	Female and male breast only and diagnosis years ≥2010



**APPENDIX J – Data Items for NPCR/SEER USCS Incidence Public Use Research Dataset**

<b>SEER*Stat Category</b>	<b>SEER*Stat Variable Name</b>	<b>Restrictions</b>
	Laterality	
Multiple Primary Fields	Sequence number – central	
Geographic Locations	Ruralurban continuum 2013 calc	Grouped into 3 categories: metro (RUCC 1-3); nonmetro (RUCC 4-9); unknown
Dates	Year of birth	
	Month of diagnosis	
Merged System-Supplied	Alcohol-related cancers	
	HPV-related cancers	
	Obesity-related cancers	
	Physical inactivity-related cancers	
	Tobacco-related cancers	
	State race eth suppress	

## APPENDIX K – NPCR/SEER – U.S. Cancer Statistics Public Use Research Database Data Use Agreement

### National Program of Cancer Registries (NPCR) and Surveillance, Epidemiology, and End Results (SEER) Incidence – U.S. Cancer Statistics Public Use Research Database Data Use Agreement

*For data submitted November, {year}*

The Centers for Disease Control and Prevention (CDC) and the National Cancer Institute (NCI) make NPCR and SEER data available to the public and researchers through various data release activities. The NPCR and SEER Incidence – U.S. Cancer Statistics Public Use Research Databases are an unrestricted subset of data submitted to CDC and NCI and made available only through the National Cancer Institute’s SEER\*Stat statistical software.

CDC has obtained an assurance of confidentiality for NPCR pursuant to Section 308(d) of the Public Health Service Act, 42 U.S.C. 242m(d). Any effort to determine the identity of any reported cases, or to use the information for any purpose other than statistical reporting and analysis, is a violation of the assurance. All direct identifiers, as well as characteristics that might easily lead to identifying individuals, are omitted from the NPCR and SEER Incidence – U.S. Cancer Statistics Public Use Research Databases. Certain demographic information has been included for research purposes; thus, all SEER\*Stat results must be presented or published in a manner that ensures that no individual can be identified. In addition, there must be no attempt to identify individuals from any computer file or to link with a computer file containing patient identifiers.

Data users must agree to the following provisions before receiving access to the NPCR and SEER Incidence – U.S. Cancer Statistics {year}–{year} and {year}– {year} Public Use Research Databases. *Please initial after each statement to indicate agreement.*

#### As the recipient of access to NPCR and SEER Incidence – U.S. Cancer Statistics Public Use Research Databases:

- I will adhere to the requirements of the Data Use Agreement and understand that my access to the data will be revoked if these requirements are violated. **Initials:** \_\_\_\_\_
- I understand that all NPCR data are owned by the states and territories. The states and territories have established agreements with CDC regarding the use and dissemination of the data. **Initials:** \_\_\_\_\_
- I will not use or permit others to use the analytic results in any way other than for statistical reporting and analysis. **Initials:** \_\_\_\_\_
- I will use appropriate safeguards to prevent use or disclosure of the information other than as provided for by this agreement. **Initials:** \_\_\_\_\_
- I will ensure all members of the research team who have access to the NPCR and SEER Incidence – U.S. Cancer Statistics Public Use Research Database through SEER\*Stat have signed this agreement. **Initials:** \_\_\_\_\_

## APPENDIX K – NPCR/SEER – U.S. Cancer Statistics Public Use Research Database Data Use Agreement

- I will not attempt to link or permit others to link NPCR and SEER Incidence – U.S. Cancer Statistics Public Use Research Data with individually identifiable records from any other dataset without CDC approval. **Initials:** \_\_\_\_\_
- I will not attempt to use the analytic results or permit others to use them to learn the identity of any person or establishment included in any dataset. **Initials:** \_\_\_\_\_
- I will take the following actions if the identity of any person or establishment is discovered inadvertently:
  - Make no use of this knowledge.
  - Notify CDC by sending an e-mail to [uscdata@cdc.gov](mailto:uscdata@cdc.gov).
  - As requested by CDC, safeguard or destroy the information that identifies an individual or establishment.
  - Inform no one else of the discovered identity. **Initials:** \_\_\_\_\_
- I will make every effort to release all statistical information in such a way as to avoid inadvertent disclosure by:
  - Ensuring that no data on an identifiable case can be derived through subtraction or other calculation from the combination of tables in the given publication. **Initials:** \_\_\_\_\_
  - Ensuring that no data permit disclosure when used in combination with other known data. **Initials:** \_\_\_\_\_
  - Not disclosing or otherwise making public data on any unit smaller than 16. If the total number of cases in a cell is fewer than 16, the cell data will be suppressed in oral and written presentations. **Initials:** \_\_\_\_\_
- I have read the data documentation file and have an understanding of the data available in the database and the restrictions related to their use. If I have questions regarding my analytic approach, I will contact CDC NPCR ([uscdata@cdc.gov](mailto:uscdata@cdc.gov)) for assistance. **Initials:** \_\_\_\_\_
- I am familiar with the use of **SEER\*Stat** in analyzing data or will complete the needed training. **Initials:** \_\_\_\_\_
- I understand that I am responsible for the results of my own analysis. The findings and conclusions resulting from the analysis of these data are those of the authors and do not necessarily represent the official position of CDC. **Initials:** \_\_\_\_\_
- I will acknowledge central cancer registries whenever data are presented, released, or published by including the following (or similar) statement:

These data were provided by central cancer registries participating in CDC's National Program of Cancer Registries (NPCR) and/or NCI's Surveillance, Epidemiology, and End Results (SEER) Program and submitted to CDC and NCI in November {date}. **Initials:** \_\_\_\_\_

**APPENDIX K – NPCR/SEER – U.S. Cancer Statistics Public Use Research Database Data Use Agreement**

- As appropriate, I will cite the data –

*For the {date}-{date} database:* National Program of Cancer Registries and Surveillance, Epidemiology, and End Results SEER\*Stat Database: NPCR and SEER Incidence – U.S. Cancer Statistics Public Use Research Database, Nov {year} submission ({year}-{year}), United States Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute. Released {date}, based on November {year} submissions. Available at [www.cdc.gov/cancer/public-use](http://www.cdc.gov/cancer/public-use).

*For the {year}-{year} database:* National Program of Cancer Registries and Surveillance, Epidemiology, and End Results SEER\*Stat Database: NPCR and SEER Incidence – U.S. Cancer Statistics Public Use Research Database with Puerto Rico, Nov {year} submission ({year}-{year}), United States Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute. Released {date}, based on November {year} submissions. Available at [www.cdc.gov/cancer/public-use](http://www.cdc.gov/cancer/public-use).

**Initials:** \_\_\_\_\_

***Users cannot be given access to the U.S. Cancer Statistics databases until SEER Research Plus access is set-up. See the instructions on page 1.***

***When you have access to SEER Research Plus, complete the fields below, sign and date the agreement, and e-mail both pages to [uscdata@imsweb.com](mailto:uscdata@imsweb.com).***

***The e-mail address you provide must be the same one used to obtain access to SEER Research Plus.***

\_\_\_\_\_  
**Signature** **Date**

Name: \_\_\_\_\_

Title and organization: \_\_\_\_\_

Telephone number: \_\_\_\_\_ E-mail address: \_\_\_\_\_

## **APPENDIX L – NPCR Data at the NCHS RDC Q&A**

### **Can you summarize the data access process?**

CDC uses the National Center for Health Statistics (NCHS) Research Data Center (RDC) as a mechanism for researchers outside of the Division of Cancer Prevention and Control (DCPC) to request and gain access to the Restricted-Access NPCR/SEER data for research purposes. The data are available through the NCHS RDC only after the standard data quality reviews that occur as part of the preparation for USCS.

The use of the NCHS RDC to manage data access provides the highest level of data security and protection of confidentiality that is available for analysis of data. Any researcher must submit a proposal that is reviewed and approved by CDC and may be reviewed by representatives from the participating central cancer registries (CCRs) before any data analysis begins. Trained data analysts at the NCHS RDC create a dataset that is customized to each analysis. The researcher can run his or her own statistical analysis or have the NCHS RDC analyst run the analysis. The NCHS RDC analyst reviews all output from statistical analysis to ensure that the researcher only conducts analyses relevant to the approved protocol and that small cell sizes are suppressed. Absolutely no individual level data will leave the NCHS RDC facilities. The data can only be accessed onsite; the NCHS RDC remote option is not available for the Restricted-Access NPCR/SEER data.

### **What is National Center for Health Statistics (NCHS)?**

NCHS is one of the national centers at CDC and is located in Hyattsville, Maryland. As the Nation's principal health statistics agency, staff at NCHS compile statistical information to guide actions and policies to improve the health of our people. More information about NCHS is available at: <http://www.cdc.gov/nchs/about.htm>.

### **What is the Research Data Center (RDC)?**

The NCHS RDC began in 1998 and has a long-standing history of managing access to health and vital statistics data through a rigorous proposal review process as well as review of the statistical output. The NCHS RDC mission is to give public access to the full range of health and vital statistics data, while protecting the confidentiality of the respondents and institutions that collected the information. There have been no breaches of confidentiality for data access through the NCHS RDC.

The NCHS RDC houses sensitive, but not classified, data. It allows access to individual data without the possibility of disclosure of identifying information. The NCHS RDC offers statistical, programming, and consulting expertise to facilitate the data analysis for research.

The NCHS RDC is a data hosting center, not a data repository. The data extracts that are hosted on the NCHS RDC are tailored specifically to the proposal and have a research life cycle. Once the analysis is completed, the data extract is archived for 2 years and then destroyed.

There are currently three modes of access through the NCHS RDC, each with specific restrictions. Access is available on-site at two locations (Hyattsville, MD and Atlanta, GA), nine Census RDCs, or through remote electronic access. More information about the NCHS RDC is available at: <http://www.cdc.gov/rdc/>

## APPENDIX L – NPCR Data at the NCHS RDC Q&A

### **Why does CDC use the NCHS RDC?**

Maintaining confidentiality is the primary objective of the NCHS RDC. Staff at NCHS RDC have statistical expertise to address confidentiality and disclosure risk. Using the NCHS RDC will allow CDC to comply with the Assurance of Confidentiality [308(d)] that was obtained for the NPCR-CSS data. All researchers must take confidentiality orientation, complete confidentiality forms, and review the disclosure manual, all of which outline practices that are essential to protecting the data and preventing disclosure of confidential information. Additionally, data housed at the NCHS RDC are not subject to the Freedom of Information Act (FOIA). More information about confidentiality is available at: <http://www.cdc.gov/rdc/B4ConfDisc/CfD400.htm>.

### **What is the research proposal process?**

The NCHS RDC has a rigorous review process for analyses proposed by any researchers wanting to use RADS data. All proposals will be evaluated by a Review Committee consisting of the NCHS RDC Director, the Confidentiality Officer, the assigned NCHS RDC analyst, and NPCR representatives. The iterative review and comment process may take 6 to 8 weeks.

Through this process, the NCHS RDC staff, the NPCR staff, and the CCR staff will fully understand the intended analysis and will be able to provide any needed direction or restrictions on the analysis and describe any limitations in what is proposed. It will be possible for CDC and participating registries to disapprove a proposal. However, guidance and re-direction as needed should be the norm. More information about the review process is available at: <http://www.cdc.gov/rdc/B3Prosal/PP300.htm>.

Once a proposal has been approved, the NCHS RDC offers a secure environment for data analyses and has processes in place to review data output for small cell sizes. This will ensure that the NPCR suppression rules are properly applied. Through the NCHS RDC, the user can conduct analyses and have remote access to data but cannot download the individual record level data or obtain counts for inappropriately small cell sizes.

The use of the NCHS RDC to host the NPCR data are a win-win opportunity because of the confidence in knowing that the data are being used correctly and safely, while at the same time making the data available for external researchers in an appropriate way. In addition, this approach will not overtax resources here in the Branch or in the CCRs. The NCHS RDC provides a level of data control beyond that of any other data access system used for registry data.

### **Who has access to the data and at what level?**

The NCHS RDC analysts will have access to the individual record level data since it is easier to create an analytic dataset using these data. The NCHS RDC analysts will be bound by the same data use agreements that CDC staff sign on an annual basis. Researchers with approved proposals will be able to conduct analyses through the NCHS RDC on the created dataset or have the NCHS RDC analyst do the analysis for them. However, they will not be able to download

## APPENDIX L – NPCR Data at the NCHS RDC Q&A

any part of the data from the NCHS RDC. Any additional variables that were not included in the original analysis proposal will need a separate approval process.

Note that this is different from the process that NPCR has used in the past where researchers with approved proposals would have direct access to the dataset itself including the ability to download the data and create a listing of individual record level data and all variables in the RADS.

Researchers have several possible modes of access to the data set created for their specific research proposal. More information is available at:  
<http://www.cdc.gov/rdc/B2AccessMod/ACs200.htm>.

### **When a researcher conducts an analysis, what type of output will he or she get?**

If a researcher is on-site at the NCHS RDC, he or she can save the results on the hard drive of the NCHS RDC computer. The NCHS RDC analyst will review the output for disclosure then either load the output onto a flash drive supplied by the researcher or e-mail the output files to the researcher. If a researcher is accessing the NCHS RDC remotely, he or she will send program by e-mail and, after disclosure review by the NCHS RDC analyst, will receive the output files by e-mail. No individual record level data are released to the researcher.

### **Will the CCRs be able to decide whether their data will be available through the NCHS RDC?**

Starting with DP17-1701, participation in all CDC-created and hosted analytic datasets and web-based data query systems, as outlined in the annual NPCR-CSS Data Release Policy, is a required strategy. [DP17-1701, 2. CDC Project Description, a. Approach, iii. Strategies and Activities, Program 3: National Program of Cancer Registries (NPCR) – Component 1, Strategy 3 Cancer Data and Surveillance (Domain 1), Data Submission (page 19)]. Therefore, data from all CCRs meeting eligibility requirements are included. Data use is important to NPCR and for continued support of the registries.

### **Will the CCRs be able to decide if their county-identifying variable (County at Dx [NAACCR#90]) is to be available for use in the NCHS RDC?**

Starting with DP17-1701, participation in all CDC-created and hosted analytic datasets and web-based data query systems, as outlined in the annual NPCR-CSS Data Release Policy, is a required strategy. [DP17-1701, 2. CDC Project Description, a. Approach, iii. Strategies and Activities, Program 3: National Program of Cancer Registries (NPCR) – Component 1, Strategy 3 Cancer Data and Surveillance (Domain 1), Data Submission (page 19)]. Therefore, data from all CCRs meeting eligibility requirements are included. County data will be used only in approved analyses and in the following ways:

- Used as a linkage variable (linkage to census data, for example) only by the NCHS RDC analyst. The county variable will not be available to the researcher but the NCHS RDC analyst would use it to create a linked dataset and then remove the county variable.

## APPENDIX L – NPCR Data at the NCHS RDC Q&A

- Included as a confounder or other control variable, but no data are presented by county. The NCHS RDC analyst will create dummy variables to mask the actual county name.
- Used in geographically aggregated form such as large metropolitan statistical areas (e.g., those with a population of 1 million or larger), multi-county regions, or geographical areas (e.g., Appalachia or IHS Contract Health Services Delivery Areas (CHSDA) counties). It will be possible for the NCHS RDC analyst to create these areas for the researcher.

**Previous data release policies indicate that the project proposals for RADS would be reviewed by the RADS working group, facilitated by CDC with representation by the CCRs. Does this procedure change now that the NCHS RDC is used?**

The CCRs will still have input on the RADS proposals. The NCHS RDC review process also includes the NCHS RDC analyst and the confidentiality officer, who will be responsible mainly for disclosure review to ensure that we abide by the 308(d) assurance of confidentiality obtained for NPCR-CSS. More information about the NCHS RDC review process is available at:

<http://www.cdc.gov/rdc/B3Prosal/PP340.htm>.

NPCR will obtain comments on each proposal from CCRs through the NPCR Central Cancer Registry Council.

**Will SEER data be included for analysis or will the data be limited to NPCR data?**

Yes. Both NPCR and SEER data may be accessed through the NCHS RDC.

**Will the NCHS RDC staff have access to SEER\*Prep and SEER\*Stat?**

No. NPCR previously provided a SEER\*Stat file to the NCHS RDC but found that researchers only used the SAS file. Therefore, the SEER\*Stat file is no longer provided.

**Will researchers have access to SEER\*Stat?**

No. As noted above, NPCR is no longer providing a SEER\*Stat file to the NCHS RDC.

**What suppression rules will be used for the RADS?**

The same suppression rules that are used for *United States Cancer Statistics*. More detailed information is available at:

[https://www.cdc.gov/cancer/npcr/uscs/technical\\_notes/stat\\_methods/suppression.htm](https://www.cdc.gov/cancer/npcr/uscs/technical_notes/stat_methods/suppression.htm).

In addition, the suppression rules for Asians/Pacific Islanders (A/PI) and American Indians/Alaska Natives (AI/AN) will also apply.

**Wouldn't it be better for researchers to contact CCRs directly for linkage studies? CDC doesn't collect personal identifiers like name or social security number.**

Yes, it would be best for researchers to contact CCRs directly for linkage studies that require individual identifiers. However, valuable public health research can be conducted with access to



## APPENDIX L – NPCR Data at the NCHS RDC Q&A

county-level data. Examples include linkage with U.S. Census data for socioeconomic analyses, or to examine regional differences in the prevalence of a specific cancer

### **Will IRB review be required for each proposal? If not, will NCHS require the researcher to obtain IRB approval before they submit their proposal?**

The NCHS RDC has an umbrella ethics review board (ERB) protocol that covers CDC employees and can be extended to external researchers. The principal investigator and all research team members who come in contact with the data must take the confidentiality orientation and complete the confidentiality forms. One of the confidentiality forms is the designated agent form (<http://www.cdc.gov/rdc/Data/B4/DesignatedAgent.pdf>), which extends the ERB to cover external researchers.

Note that the ERB protocol serves the same function as an institutional review board (IRB) protocol. At CDC, there is one office that coordinates the submission and tracking of human research protocols. However, other centers such as NCHS and the National Institute of Occupational Safety and Health, have different names for these review boards: Research Ethics Review Board (ERB) at NCHS and Human Subjects Review Board (HSRB) at NIOSH.

Researchers may choose to obtain an IRB from their own institution, but it will not be a requirement in the application process given the ERB extension that the NCHS RDC provides.

### **Does access to the RADS cost anything?**

No. CDC covers the cost of analyzing RADS through the NCHS RDC.

### **As more researchers become aware of the RADS, they may want access to additional variables that CCRs submit to CDC. How will this process be handled?**

The addition of new variables in RADS will be discussed with CCRs prior to their inclusion in the data release policy, which is updated annually.

### **How is access to the comparative effectiveness research (CER) dataset managed?**

Access to the CER dataset are managed through the same NCHS RDC process. The proposal process will not differ except that staff from the Specialized Registries funded for CER data collection will review these proposals.

## APPENDIX M – Data Items for Restricted-Access Dataset (RDC)

The restricted access dataset are individual case-specific data derived from the NPCR-CSS dataset. The data are available to researchers at NCHS Research Data Centers as a SAS file. SAS files are created specifically for each project’s needs. The data items that may be requested by researcher are listed below.

<b>Variable Name</b>
Alternate Patient ID Number
Address at Diagnosis – State
Address at Diagnosis – County at Analysis*
USCS Standard
USCS9919
USCS1519
USCS9819
USCS1019
Address at Diagnosis – Census Region
Race 1
Race 2
Race Recode
Econ Status
State race eth suppress
Spanish/Hispanic Origin
IHS Link
Sex
Age at Diagnosis**
Age Recode
Birth Date***
Econ status
Rural-urban continuum 2013
Sequence Number – Central
Date of Diagnosis****
Primary Site
Laterality
Grade
Grade Clinical
Grade Pathological
Grade Post Therapy
Diagnostic Confirmation
Type of Reporting Source
Histologic Type ICD-O-3
Behavior Code ICD-O-3

## APPENDIX M – Data Items for Restricted-Access Dataset (RDC)

Behavior Recode for Analysis Derived/WHO 2008
Primary Site Recode
SEER International Classification of Childhood Cancer (ICCC) Recode Extended ICD-O-3/WHO 2008
AYA Site Recode 2020
Lymphoma Neoplasm Recode 2020 Revision
SEER Summary Stage 2000
SEER Summary Stage 1977
Derived SS2000
Summary Stage 2018
Merged Summary Stage
RX Summ – Surg Prim Site
Merged radiation
CS Site-Specific Factor 1
Merged Estrogen Receptor
Merged Progesterone Receptor
Merged HER2 Receptor
Over-ride Age/Site/Morph
Over-ride SeqNo/DxConf
Over-ride Site/Lat/Sequence Number
Over-ride Site/Type
Over-ride Histology
Over-ride Report Source
Over-ride Ill-define Site
Over-ride Leuk, Lymphoma
Over-ride Site/Behavior
Over-ride Site/Lat/Morph
Alcohol-related cancers
HPV-related cancers
Obesity-related cancers
Physical activity-related cancers
Tobacco-related cancers

\* County data will be used only in approved analyses and in the following ways: a) used as a linkage variable (linkage to census data, for example) only by the NCHS RDC analyst; b) included as a confounder or other control variable, but no data are presented by county; c) used in geographically aggregated form such as large metropolitan statistical areas (e.g., those with a population of 1 million or larger), multi-county regions, or geographical areas (e.g., Appalachia or IHS Contract Health Services Delivery Areas (CHSDA) counties)

\*\*Age over 99 is recoded

\*\*\*Only year is provided; if age is over 99, year of birth is recoded

\*\*\*\*Day of diagnosis is not provided

## APPENDIX N – NPCR-CSS Levels of Data Access

### NPCR-CSS Levels of Data Access

#### *Internal Analytic Datasets*

Includes: Record level information, Survival dataset, Prevalence dataset, Delay Adjusted dataset  
Criteria: USCS criteria met, <6 cases cell suppression, complementary cell suppression  
Availability: DCPC, SEER, IHS researcher or contractor

Access: Signed Data Use Agreement and Non-Disclosure Agreement, Assurance of Confidentiality training

Is a state or county used and identified?

No

No additional permission needed; should document its use and include proper acknowledgment

Yes

Data published in USCS?

Yes

No

States notified of study results

#### *Federal/Trusted Partners*

Includes: Record level information; may include Survival dataset, Prevalence dataset, Delay Adjusted dataset  
Criteria: USCS criteria met, <16 cases cell suppression, complementary cell suppression  
Availability: ACS, CBTRUS, IACR, CONCORD, AHRQ, OWH, CDI, CDC's Tracking Program

Access: Signed Data Use Agreement and Non-Disclosure Agreement; may include MOU

#### *External Restricted Access*

Includes: Includes record-level information  
Criteria: USCS criteria met  
Availability: Researcher outside DCPC through NCHS RDC

Access: Proposal submitted to NCHS RDC, signed Data Use Agreement and Non-Disclosure Agreement

NPCR and RDC review; may include state

## APPENDIX N – NPCR-CSS Levels of Data Access

### NPCR-CSS Levels of Data Access Public Use Datasets

#### *USCS Data Visualizations tool*

Includes: State, county, region, and Congressional-district levels, no record-level information

Criteria: USCS criteria met, permission provided on Dataset Participation Agreement, <16 cases cell suppression enforced

Availability: Public

#### *CDC WONDER*

Includes: State, county, region, and MSA levels, no record-level information

Criteria: USCS criteria met, permission provided on Dataset Participation Agreement, <16 cases cell suppression enforced

Availability: Public

#### *State Cancer Profiles*

Includes: State and county levels, no record-level information

Criteria: USCS criteria met, permission provided on Dataset Participation Agreement, <16 cases cell suppression enforced

Availability: Public

#### *NPCR/SEER USCS Public Use Dataset*

Includes: State record-level information, no case listing

Criteria: USCS criteria met, permission provided on Dataset Participation Agreement, <16 cases cell suppression enforced

Availability: Public after signed Data Use Agreement and Non-Disclosure Agreement, annual agreements required

No additional permission needed; users should document its use and include proper acknowledgment

**NPCR-CSS 2021 Data Release Policy**

**August 2021**

**1995–2020 Diagnosis Years**

## APPENDIX O – Data Items for NPCR/SEER USCS Delay Adjusted Database

SEER*Stat Category	SEER*Stat Variable Name
Age at Diagnosis	Delay age Age recode with single ages and 85+
	Age recode with <1 year olds
Race, Sex, Year Dx, Registry, County	Sex
	Year of diagnosis
	Addr at DX – state
	County at DX Analysis
	State-county
	Origin recode NHIA (Hispanic, Non-Hispanic)
Required Delay Fields	Delay factor
	Delay site
	Race and origin recode (NHW, NHB, NHAIAN, NHAPI, Hispanic)
	Delay race (All, Race recode (White, Black, AIAN, CHSDA, API, Hisp, Non-Hisp)
Site and Morphology	Behavior recode for analysis derived/WHO2008
Multiple Primary Fields	Sequence number - central

## APPENDIX P – Data Items for NPCR Prevalence Database

SEER*Stat Category	SEER*Stat Variable Name
Age at Prevalence Date	Age at Prevalence Data (Calculated)
Age at Diagnosis	Age recode with single ages and 85+
Race, Sex, Year Dx, Registry, County	Sex
	Year of diagnosis
	Addr at DX – state
	County at DX Analysis
	State-county
	NPCR project flag
	Economic status
	Race and origin recode (NHW, NHB, NHAIAN, NHAPI, Hispanic)
	Race and origin recode (NHW, NHB, NHAIAN, NHAPI, Hispanic)
	State
	County
	Race recode (White, Black, Other)
Site and Morphology	Primary Site – labeled
	Histologic Type ICD-O-3
	Behavior Code ICD-O-3
	Grade
	Diagnostic confirmation
	ICD-O-3-Hist/behavior, labeled
	ICD-O-3-Hist/behavior, malig, labeled
	Site recode ICD-O-3/WHO 2008
	ICCC site recode ICD-O-3/WHO 2008
	Behavior recode for analysis derived/WHO2008
Stage – LRD [Summary and Historic]	Derived SS2000
	SEER Summary Stage 2000
	Merged Summary Stage 2000
Extent of Disease – CS	CS Site-Specific Factor 1
	CS Site-Specific Factor 2
	CS Site-Specific Factor 15
	Laterality
Cause of Death (COD) and Follow-up	Survival months – presumed alive
	Survival months flag – presumed alive
	Cause of death (ICD-10)
	ICD revision number
	Vital status
	Follow-up source central

## APPENDIX P – Data Items for NPCR Prevalence Database

SEER*Stat Category	SEER*Stat Variable Name
	COD exclusion flag
	Original vital status
	Vital status recode (study cutoff used)
	Cause of death recode
	COD recode with Kaposi and mesothelioma
Multiple Primary Fields	Sequence number - central
Race and Age (case data only)	Age at Diagnosis
	Race 1
	NHIA derived Hispanic origin
Dates	Presumed alive year of last contact recode
	Presumed alive month of last contact recode
	Presumed alive day of last contact recode
	Year of birth
	Month of diagnosis
	Day of diagnosis
	Original day of last contact
	Original month of last contact
	Original year of last contact
	Original year of diagnosis
	Original day of diagnosis
	Original month of diagnosis
Other	Type of Reporting Source
User-Specified	EDPMDE LinkVar